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My PhD three years course in Drug Discovery & Development at the 
Department of Pharmacy of Salerno University was started in 2014 under the 
supervision of Prof. Carmela Satunino.  
In the first part of my project, the research was mainly focused on the design 
and synthesis of new anti-cancer agents. In particularly, were designed two 
series of compounds as new modulators of C-terminal domain of the 
molecular chaperone Heat Shock protein 90 (Hsp90), these compounds were 
designed on the base of the first synthetic inhibitor of C-terminal domain of 
Hsp90.  
In the second part of my research activity was focused on the design and 
synthesis of new inhibitors of microsomal Prostaglandin  E2 synthase-1 
(mPGES-1) as potential anti-inflammatory agents.  
The work was performed under the direct supervision of Prof. Carmela 
Saturnino and in collaboration with Prof. Ines Bruno and Dr. Stefania 
Terracciano. Computational guided design of compounds was performed in 
collaboration with Prof. Giuseppe Bifulco‟s research group. Biological 
screenings were performed in collaboration with Prof. Oliver Werz of 
Friedrich Schiller University (Germany) in the case of mPGES-1, and with Dr. 
Maria Carmela Vaccaro and Fabrizio Dal Piaz of Salerno University in the 
case of Hsp90. 
Furthermore, to improve my knowledge about the synthesis techniques, in 
2016 I joined Prof. Patrick Dallemagne's research group at the Centre d'Etudes 
et de Recherche sur le Médicament de Normandie de l'Université de Caen 
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One of the main goal of modern medicinal chemistry is the development of 
new agents able to modulate biological targets involved in inflammation and 
cancer processes. In this context, my PhD project was focused on the 
exploration and structural optimization of various chemical moieties able to 
interfere with two targets involved in both processes. In particular, two 
biological targets were selected: Heat shock protein 90 (Hsp90) and 
microsomal Prostaglandin E2 Synthase-1 (mPGES-1). The results obtained can 
be divided into two sections in accordance with the target of interest. 
 
a) Exploration and structural optimization of DHPM core in order to 
guide the synthesis of new and more potent Hsp90 C-terminal 
inhibitors.  
 
Hsp90 is a molecular chaperone involved in the maturation and stabilization of 
a wide range of client proteins that play a crucial role in the development, 
survival and proliferation of cancer cells. In the literature there are several 
compounds capable of inhibiting this molecular chaperone. The most part of 
these compounds inhibit the protein through modulation of the N-terminal 
domain. However, this type of modulation involves a well-known heat shock 
response, a cytoprotective mechanism that as a final result leads to the increase 
of cytosolic levels of heat shock proteins with consequent cell survival. 
Therefore, the modulation of  C-terminal domain of Hsp90 represents a better 
strategy for the development of new antitumor agents, since, they do not 
induce heat shock response. In an attempt to discover new modulators of the 
C-terminal domain of Hsp90 and taking into account the structure of the first 
synthetic inhibitor of this domain, a 3,4-dyhidropyrimidin-2(1H)-one (DHPM) 
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derivative, two more generations of DHPM derivatives have been synthesized. 
Relatively to the second generation of DHPM derivatives, the synthesis was 
focused on the influence of the chemical functionalization of aromatic ring at 
C4 position of DHPM core, while the third generation has been designed with 
the aim to functionalize the C2 position of the core. The exploration and 
optimization processes of DHPM core led to the identification of novel and 
more potent inhibitors of the C-terminal domain of Hsp90.  
 
b) Identification of new mPGES-1 inhibitors.  
mPGES-1 is an inducible enzyme that catalyzes the terminal step of the 
biosynthesis of PGE2 from the PGH2 precursor. The inhibition of this enzyme 
appears to be a promising strategy for the identification of novel anti-
inflammatory agents, because, the use of selective inhibitors would allow to 
overcome the classical side effects of traditional anti-inflammatory drugs. 
Moreover, mPGES-1 is overexpressed in a wide variety of human cancers and 
for this reason it has emerged as an attractive biological target for anticancer 
drug discovery. In order to identify new molecular platforms able to interact 
with the target protein three collections of compounds (carbazoles, biaryl 
compounds and 5-pyrazolones) were synthesized. Biological evaluation 
revealed the identification of five biaryl compounds (60-64) as new chemical 
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1.1 A short history of anticancer therapy 
"Cancer" term includes a group of more 100 diseases in which the cells begin 
to grow out of control.
1
 With the onset of tumorigenesis body cells begin to 
divide and spread into the surrounding tissue. In addition, it is possible that 
some tumor cells can break off from the primary tumor and through the blood 
stream or the lymph system create a secondary tumor far from the original in a 
process known as metastasis.
2
 The processes that trigger oncogenesis are 
varied and are not yet well defined, to date many risk factors have been 
identified that could increase the chance of getting cancer, for these reason it is 
nearly impossible to know the development of cancer causes.
3,4
 The tumor 
arises from a normal cell when its DNA is damaged fact, the cancer is a 
disease characterized by a large genetic instability. When the DNA of cells is 
damaged and the repair mechanisms do not work there is an upheaval of 
cellular functions. In cancer cells, indeed the damaged DNA is not repaired, 
and the cell does not die, instead it gives rise to more such abnormal cells with 
abnormal DNA.
5
 In most cases surgery is the main strategy to remove the 
tumors, while chemotherapy and radiotherapy are used especially to remove 
residual cells by acting on their continued proliferation.
6 
Unfortunately, the 
chemotherapy and radiotherapy don't have a real specificity of action and they 
cause considerable side effects.
7 
  
The coming of the nitrogen mustards and antifolate drugs have allowed the 
first chemotherapy treatment only in 1940. While, radiotherapy has become a 
valuable resource for the control of this disease in 1960 with the invention of 
the linear accelerator.
8
 At that time the main strategies in cancer therapy were 
surgery and radiotherapy, but soon it became clear that cure rates after ever 
more radical local treatments had plateaued at about 33% due to the presence 
of heretofore unappreciated micrometastases. After these observations, it was 
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decided to introduce the opportunity to apply chemotherapy drugs in 
conjunction with surgery and/or radiation treatments, doing so the concept of 
adjuvant chemotherapy was born. The purpose of the combined treatment 
modality was to maximize the antitumor effect of each of the three therapies 
with minimal toxicity to normal tissues.
9,10
 Over time, it was needed to 
develop an effective therapies not based only on empirical observations but 
increasing dependent on an understanding of human tumour biology.
11
 With 
this purpose doctors, researchers, and patients worked together to improve 
treatment options and identify new drugs that have action on a selected 
biological entities, with this new concept, chemotherapy entered into the era of 
"targeted therapy". The new concept of the identification of biological targets 
is started in 1960 with an unrelated program, the Special Virus Cancer 
Program (SVCP), which wanted to clarify the association between viruses 
with cancer.
12  
When it failed in its purpose it was transformed into a program 
of molecular biology to study genes that have been aggregated by tumor 
viruses. This work identified oncogenes, suppressor oncogenes, and signaling 
pathways essential for developmental biology itself.
13 
In order to understand 
the cellular activities such as proliferation and survival and with the aim to 
repair the molecular defects directly in cancer cells, researches of 
biotechnology firms were focused on the molecular and biological processes. 
Molecular targeting offers a more convenient solution for the development of 
potential therapeutic agents with reduced systemic toxicity, on the other hand 
the tumor cells, thanks to their intrinsic genetic plasticity, easily adapt to a new 
environment. Finally, this study led to the identification of new drug targets 
which currently influences the development of anticancer drugs. New targets 
include growth factors, signalling molecules, cell-cycle proteins, modulators 
of apoptosis and molecules that promoted angiogenesis.
14 
In the last decades, 
have been discovered many differences between normal cells and tumor cells, 
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many of which help the proliferation of cancer cells, therefore, scientific 
research has accelerated the development of new anticancer drugs with the 
main objective to offer a real hope to all those who suffer from cancer. 
 
1.2 Inflammation 
Inflammation is defined as the immediate body's response when it feels 
threatened by pathogens, noxious stimuli such as chemicals, or physical 
injury.
15
 This process leads defensive cells at the site of the damage so as to 
neutralize and eliminate the noxious stimulus, repair the structure and restore 
the function of damaged tissues. Clinically inflammation is characterized by 
four cardinal signs which they were reported in the first century by Celsus, 
they are: redness (rubor), heat (Calor), swelling (tumor) and pain (dolor).
16
 
Later Virchow has added a fifth signs: loss of function (functio laesa).
17
  
Figure 1.1 Rappresentation of cardinal signs of inflammation 
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Inflammation is a generic response, and therefore it is considered as a 
mechanism of innate immunity, compared to adaptive immunity which is 
specific for each pathogen.
18
 Furthermore, the inflammation damage has 
substantial differences from the damage of autoimmune disease that determine 
a specific immune-mediated attack on the tissue that is no longer recognized 
as self.
20 
Based on the time duration, the evolution of inflammation can be 
classified as either acute or chronic.
21
 The first response observed after a 
noxious stimulus is acute inflammation which as consequence increases the 
contribution of leukocytes (mainly granulocytes) from the blood to damaged 
tissue, while chronic inflammation is a more prolonged response resulting 
from the persistence of the mediators of inflammation of an acute 
inflammation not completely resolved.
22
 Historically the first anti-
inflammatory drugs have their origin in the discovery of some plant extracts 
that gave relief to disorders related to inflammation. In the mid-19
th
 century 
were discovered salicylates, this has allowed the development of some drugs 
such as acetyl-salicylic acid (Aspirin).
23 
With the discovery of the mechanism 
of action of aspirin it is exponentially increased the interest of the 
development of new anti-inflammatory therapies which have as mechanism of 
action the inhibition of cyclooxygenase (COX).
24
 However, many side effects, 
particularly related to gastrointestinal and cardiovascular toxicity, were 
associated with the use of these drugs.
25
 This toxicity appears to be a serious 
drawback in a long-term therapy,
26
 so today, the development of small 
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1.3 Why cancer and inflammation? 
 
The relationship between cancer and inflammation is a concept that has been 
observed many years ago, however, the mechanisms underlying this 
interconnection are still unclear. Cancer and inflammation go hand in hand, 
the first triggers an inflammatory response, while the inflammatory 
microenviroment increases the aggressiveness of the tumor and the 
dissemination of metastases.
27
 The connection between cancer and 
inflammation was observed in the nineteenth century, when they noticed that 
the tumors arose in a chronic inflammation sites and when  inflammatory cells 
were found in biopsy samples from tumors.
28 
It is well known that many 
chronic inflammatory factors increase the risk of developing cancer, this 
factors include autoimmune diseases (inflammatory bowel disease is 
associated with colon cancer), microbial infections (infection with 
Helicobacter pylori is associated with gastric cancer and gastric mucosal 
lymphoma) and inflammatory conditions of unknown origin (prostatitis is 
associated with prostate cancer).
29
 The link between inflammation and cancer 
can be divided into two pathways as shown in Figure 1.2.
30
 The intrinsic 
pathway is activated by genetic events as oncogenes activation, 
oncosuppressor inactivation and chromosomal rearrangement or amplification, 
in this manner cells are transformed producing an attractive environment for 
tumour growth, facilitating genomic instability and promoting angiogenesi.
31
 
The extrinsic pathway is mediated by inflammatory cells of innate immunity, 
so, inflammatory or infectious conditions enhance the risk of developing 
cancer (for example, such as inflammatory bowel disease for colorectal cancer 
and prostatitis for prostate).
32
 The two pathways activate the transcription 
factors, such as nuclear factor-κB (NF-κB), signal transducer and activator of 
transcription 3 (STAT3) and hypoxia-inducible factor 1α (HIF1α), in tumour 
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 that coordinate the production of inflammatory mediators, including 




Figure 1.2 Pathways that connect inflammation and cancer 
The cytokines activate the same transcription factors in inflammatory cells, 
stromal cells and tumour cells, resulting in more inflammatory mediators 
being produced and a cancer-related inflammatory microenvironment being 
generated. On the other hands, inflammatory mediators contribute to genomic 
instability resulting to the known mutations associated with tumours. Many of 
them act as direct mutagens or as deregulators of DNA repair mechanism and 
cell cycle checkpoints acquiring the ability of cancer cells to proliferate, 
invade and escape from host defence.
35,36
 Moreover, the relationship between 
cancer and inflammation is well documented by numerous studies that 
demonstrate how aspirin is able to prevent certain cancer such as colorectal, 
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lung, stomach, esophagus and prostate.
37-39
Anyway, many evidences have 
been gathered supporting the improved therapeutic efficacy that can be 
achieved by blocking the two signalling networks and their pathways.
40,41
 In 
this way, my PhD project has worked. 
 
1.4 The drug discovery  
 
The development of new drugs requires a complex process involving many 
scientific areas, such as, biology, statistics, pharmacology, pharmaceutical 
chemistry, toxicology, computational chemistry, organic chemistry and 
proteomics.
42
 The network between the various areas of science cleared the 
way for what we now call the “drug discovery process”. The aim of drug 
discovery is to turn “molecules into medicine for the public health”, this means 
find new therapeutic agents with suitable pharmaceutical properties (i.e., 
efficacy, bioavailability, toxicity) for preclinical evaluation. The drug 
discovery is one of the most challenging human activities, these processes 
must proceed through several stages in order to produce a product that is safe, 
efficacious, and has passed all regulatory requirements.
43
 This process begins 
with the "target identification". Any enzyme or any biochemical mechanism 
involved in the pathological condition may represent a potential therapeutic 
target. After the identification there is the step of target validation, which takes 
place indirectly, ie through the use of compounds that block the target thus 
giving the desired effect.
44
 Furthermore, the process of discovery of new drugs 
requires the knowledge of pharmaceutical technology to make new 
bioavailable products without losing the pharmacological effect, for this 
purpose it is requires a close collaboration between a pharmaceutical and 
chemical pharmaceutical technologist.
45 
Currently, the drug discovery process 
is focusing on small organic molecules, appropriately designed to act directly 
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on the biological target of interest, without interacting with other biological 
system.
46 
However, drug discovery requires simple and variable methods of 
synthesis to vary the lead structure extensively, which is essential for the 
derivation of structure–activity relationships (SARs, ligand-based design) and 
rapid optimization to obtain the active ingredient. The efficient optimization of 
drugs and the provision of sufficient amounts for further biological 
characterization is the central task of medicinal chemistry.
47 
Today, 
researchers employ various techniques to overcome the difficulties in the 
drugs discovery process, for example, analytical and purification methods such 
as high-performance liquid chromatography (HPLC),
48
 multicomponent and 
domino reactions,
27
 microwave-assisted and flow chemistry,
49,50
 etc. In the 
present PhD project, thanks to combined of medicinal and pharmaceutical 
chemistry approaches, new chemical entities with antitumor or anti-
inflammatory effects have been successfully identified. With the aim of 
discovering new potential anticancer agents I focused my attention on 
exploration and structural optimization of the first synthetic inhibitor of C-
terminal domain of Heat shock protein 90. After completion of this project I 
had the opportunity to work on a second project aimed to identification new 
anti-inflammatory agents that target the microsomal Prostaglandin E2 
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1.5 Heat shock protein 90 (Hsp90) 
 
Exposure of cells to stress conditions (including heat shock, oxidative stress, 
heavy metals), or pathologic conditions such as ischemia and reperfusion,  
inflammation, tissue damage, infection, usually cause protein dysfunction.
51
 
The cell responds to environmental stress by increasing synthesis of several 
molecular chaperons with the aim to prevent cellular damage and to re-
establish cellular homeostasis.
51
 These proteins help to maintain cellular 
cellular homeostasis (proteostasis) in cells, in fact,
 
in accordance with the 
general definition, molecular chaperone are each protein that helps or 
stabilizes another protein to acquire its functionally active conformation
52 
and 
prevent the aggregation of non-native protein.
53
 In the cells, several different 
classes of chaperones exist, many of these classes  are often known as stress 
proteins or heat-shock proteins (HSPs), as they are upregulated under 
conditions of stress in which the concentrations of aggregation-prone folding 
intermediates increase. Heat Shock proteins are categorized according to their 
molecular weight into six classes: small Hsps, Hsp40, Hsp60, Hsp70, Hsp90 
and Hsp100.
54 
Family members of Hsps are localized in the nucleus, 
cytoplasm, and subcellular compartments, such as mitochondria and 
endoplasmic reticulum (ER), the high molecular weight HSPs are ATP-
dependent chaperones, whereas small HSPs act in an ATP-independent 
manner.
55
 It is important to emphasize that the expression of HSPs requires a 
precise balance, because, over-expression of some HSPs shows the way to 
certain diseases such as cancer. Tumor cells having more signal transduction 
pathways and a higher metabolic requirements than normal cells, so they have 
a greater need of chaperones to maintain cancer cells survival. 
56 
For these 
reasons, the expression of Hsps is severely elevated in cancer cells, and it is 
associated with enhanced tumorigenicity, metastatic potential of cancer cells 
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and resistance to chemotherapy. Moreover, in association with key apoptotic 
factors they are strong anti-apoptotic proteins, blocking the cell death process 
at different levels, for these reasons they are suitable targets for modulating the 
streets of cell death.
57 
Among the Hsps's family, heat shock protein 90 (Hsp90) 
has emerged as being of prime importance to the survival of cancer cells.
58 
Hsp90 is constitutively expressed at 1-2% of total cytosolic proteins and its 
level increases up to 10-fold in tumor cells, suggesting that it may be critically 
important for tumor cell growth and/or survival.
59
 Firstly, Hsp90 protein is 
involved in the maturation and stabilization of a wide range of ‘client proteins’ 





 neurodegenerative diseases, 
viral infections and cancer.
62
 Regarding the latter, many Hsp90 client proteins 
are involved in critical cellular functions that promote cell growth, cell 
survival and proliferation as they are able to facilitate an escape from normal 
proteolytic turnover, thereby overall promoting an oncogenic transformation.
63
 
Hsp90 client proteins comprise proteins that contribute to all of the six 
hallmarks of cancer, including the ability to produce growth factors, resistance 
to anticancer agents, avoidance of apoptosis, unlimited replicative potential, 
uninterrupted angiogenesis and invasiveness and metastasis.
64-66
 Hsp90 play a 
central role in acquisition and maintenance of each of six hallmarks of cancer 
(Figure 1.3). For example, Hsp90 influences angiogenesis by folding hypoxia-
inducible factor‑1α (HIF‑1α) and vascular endothelial growth factor receptor 
(VEGFR) in addition to governing nitric oxide synthase upregulation. Many 
client proteins of Hsp90 are apoptotic mediators, including Bcl-2, Apaf-1, the 
serine-threonine protein kinase AKT/PKB and survivin.
67
 Also, Hsp90 may 
promote tissue invasion and metastasis through MMP-2 activation, or 
digesting extracellular matrix proteins.
67
 Other client proteins of Hsp90 that 
play a role in cell signaling processes include FAK (integrin pathway), IL6R 
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(JAK/STAT3 pathway), IκB kinases (NFκB pathway), CDK 4, 6, 9, hTERT 
(cell cycle), p53 (tumor suppressor genes), and the steroid hormone receptors 
(estrogen receptor and androgen receptor).
68 
 
Figure 1.3 Hsp90 functions implicated in establishment of each of the hallmarks of cancer. 
Importantly, Hsp90 functions may also permit the genetic instability on which acquisition of 
the six hallmarks depends. 
In addiction, Hsp90 exists as a multi-chaperone complex with unusually high 
affinity for ATP and some substances in tumor cells, whereas in normal cells a 
latent form of Hsp90 protein is present. In the human proteome there are four 
isomers of Hsp90, the two major isoforms correspond to the inducible Hsp90α 
isoforms and the costitutive Hsp90β, that are located predominantly in the 
cytosol, whereas two non-cytosolic forms are known, the 94 kDa glucose-
regulated protein (GRP94) and the Hsp75/tumor necrosis factor receptor 
associated protein 1 (TRAP-1), that are expressed in the endoplasmic 
reticulum and in the mitochondrial matrix respectively.
69
 Structurally, this 
enzyme exist as a homodimer and each monomer contains three flexibly 
linked regions.
70
 The amino (N)-terminal domain consists of a α- and β-
sandwich motif, it is responsible for the protein‟s ATPase activity, since that 
contains an adenosine triphosphate (ATP)‑binding and hydrolyzing pocket.71 
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Another intriguing characteristic of the N-terminal domain is that several 
conserved amino acid residues form a “lid‟ (residues 100–121) that closes 
over the nucleotide binding pocket in the ATP bound state but is open during 
the ADP-bound state.
72 
The middle domain consist of a large αβα segment 
connecting to a small αβα segment via several short α-helices,
73
 it is a linker 
region involved in co-chaperones and client proteins recognition/binding, also 
participates in forming the active ATPase.
74
 Finally, there is the carboxy (C)-
terminal domain consist of a curved α-helix, a three-stranded β-sheet, a three-
helix coil and an extended disordered arm, this region directs Hsp90 
dimerization.
73
 This region contains another ATP-binding site, without  
hydrolases activity, this pocket is only available when the N-terminal domain 
ATP binding site is occupied.
74-76
 In particulary, the C-terminal domain is 
implicated into the functional switch between the closed and the open protein 
conformation,
77
 and there is a conserved MEEVD motif involved in the 
binding of co-chaperones which containing a tetratricopeptide repeat (TRP) 
motif.
78,79
 Hsp90 helps nascent proteins to assume their biologically active 
conformations, corrects the conformation of misfolded proteins, and helps 
incorrigibly misfolded proteins to be removed and degraded by the ubiquitin-
proteosome system through the presence of co-chaperones, immunophilins, 
and partner proteins to form multiprotein complexes, thus facilitates the 
maturation, stability, activity of client proteins.
80-83  
ATP hydrolysis is necessary for Hsp90 activity.
84
 Structural studies showed 
that Hsp90 assumes several structurally distinct conformations. In the resting 
state, through the dimerization of its C-terminal domain, Hsp90 forms a V 
shape conformation which is defined as the “open conformation”.
85 
The ATP-
binding N-terminal domain of Hsp90 induces a series of conformational 
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After lid closures, Hsp90 reaches a more compact conformation, termed 
“closed conformation” in which the N-domains are dimerized. After Hsp90 
finishes its chaperoning tasks of assisting the proper folding, stabilization and 
activation of client proteins under the active state, the ATP molecule is 




Figure 1.4 Conformational cycle and schematic domain organization of Hsp90  
During different phases of the chaperone cycle Hsp90 binds more than 20 co-
chaperones through both the N- and C-termini of the protein, some of which 
play the tuning roles by either activating or inhibiting the ATPase activity of 
Hsp90.
88-90 
Hsp90 contains several drugable sites at both its N- and C-terminal 
domains and for this reason, Hsp90 inhibitors are divided into several groups. 
Traditional Hsp90 inhibitors block the binding of the ATP at N-terminal 
domain, they include natural compounds, as geldanamycin (GDA) and 
radicicol (RDC),
91,92
 and synthetic molecules such as geldanamycin and 
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 C9-type iridoid (verminoside)
103
 and the three 
chimeric compounds of radicicol and geldanamycin radamide, radester and 
radanamycin.
104-106
 Even today, there are over 50 clinical trials testing 
different N-terminal Hsp90 inhibitors (ClinicalTrials.gov database) 
undergoing clinical evaluation.
107,108
 However, clinical trials have shown 
many limitations, including poor solubility and toxicity of these drugs that 
limit their use.
109
 The most well-known side effect is the induction of a 
cytoprotective mechanism termed as heat shock response (HSR),
110,111
 which 
induces drug-resistance and anti apoptotic mechanisms.
112,113
 A promising 
strategy to overcome these problems is to regulate Hsp90 function by targeting 
the C-terminal domain, as its inhibition does not induce the unsought 
HSR.
114,115
 Unfortunately, the few structural information on Hsp90 C-terminal 
domain currently obtainable have not provided the resolution necessary for 
structure-based drug design of new synthetic inhibitors. The development of 
more efficacious C-terminal inhibitors is desired to better understand the 
ramifications of C-terminal inhibition and to probe the mechanism by which 
Hsp90 interacts with client proteins.
116
 The first C-terminal inhibitor was 
discovered in 2000 by Neckers and co-workers, they showed the capabilities 
of the Hsp90 C-terminus to bind novobiocin.
117 
Novobiocin is not the only 
product which inhibits the Hsp90 activity through C-terminus modulation, but 
related family members such as chlorobiocin and coumermycin A1 were 
showed to bind this domain and  induce a dose-dependent degradation of 
Hsp90 client proteins in a manner similar to Hsp90 N-terminal inhibitors.
118
 
However, these inhibitors have micromolar and millimolar IC50 values 
(Novobiocin ≈ 700 µM in SKBr3 cells) and it is not sufficient for clinical 
application,
115 
but it give a starting point for the development of new more 
efficacious C-terminal inhibitors. Furthermore, structural optimization of 
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novobiocin has led to analogues with more potent antiproliferative profiles 
than the starting compound.
119-122
 Many other inhibitors that bind C-terminal 







and sansalvamide A derivatives (Table 1).
126,127  
The latter are the allosteric modulators that bind the N-middle domain and 
block the binding of Hsp90 to client proteins and co-chaperones that bind to 
the C terminus of the protein.
128
 Until now, only natural and/or semi-synthetic 
compounds have been described. Recently, Strocchia et al. have identified the 
first synthetic compound able to inhibit C-terminal domain of the Hsp90 
(Table 1).
129
 The principal benefit of C-terminal inhibitors is that they do not 
seem to be associated with the heat shock response than N-terminal 
inhibitors.
130 


















































As described before, Hsp90 is the central point of the protein folding machine, 
because there are many binding sites for co-chaperones. So, each protein-
protein interaction presents the opportunity for disruption the protein folding 
process. Nowadays, only a few protein-protein interactions have been targeted 





and the interactions between Hsp90 and the partner protein HOP.
133
However, 
the modulation of Hsp90 through the last two strategies (C-terminal inhibitors 
and disrupt protein-protein interaction), may allow to develop of new potential 
modulators of Hsp90 which could be used as anticancer agents and are 
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1.6 Microsomal prostaglandin E2 synthase-1 (mPGES-1) 
 
Prostaglandins (PGs) and thromboxane A2 (TXA2), collectively termed 
prostanoids, are a group of physiologically active lipid mediators derived 
enzymatically from fatty acids. This class of mediators are involved in 
homeostatic functions and mediate pathogenic mechanisms, including 
inflammatory response.  
Inflammation is the body's natural response to infection and injury against an 
organ or tissue and has been implicated in the pathogeneses of arthritis, cancer 
and stroke, as well as in neurodegenerative and cardiovascular disease.
134 
Furthermore, inflammatory diseases increase the risk of developing many 
types of cancer such as bladder, cervical, gastric, intestinal, oesophageal, 
ovarian, prostate and thyroid cancer.
135,136 
There are four principal bioactive 
prostaglandins generated: prostaglandin E2 (PGE2), prostacyclin (PGI2), 
prostaglandin D2 (PGD2) and prostaglandin F2α (PGF2α).
137 
Biosynthesis of 
prostanoids starts by release of arachidonic acid (AA) from cell membrane 
phospholipids catalyzed by phospholipase A2 (PLA2). Subsequently AA 
is converted to Prostaglandin H2 (PGH2) in two steps by cyclooxygenase 1/2 
(COX-1, COX-2), bifunctional enzymes that contain cyclooxygenase and 
peroxidase activity, in the first step AA was oxidized to generate PGG2, then 
this intermediate is reduced into PGH2.
138 
The COX pathway produces PGG2 
and PGH2, which then are converted into PGI2 by prostacyclin synthase, TXA2 
by thromboxane synthase, and PGE2, PGD2 and PGF2α by their respective 
synthase enzymes (Figure 1.5).
139  
Among the prostaglandins, PGE2 is the most abundant in physiological 
conditions and plays a crucial role in several organs and tissues such as kidney 
and gastrointestinal tract.
139,141
 Further studies suggest that PGE2 had 
immunosuppressive effects by regulating the expression of EP2, EP3 and 
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 also, PGE2 protected the gastrointestinal mucosa and regulated the 
renal flow, natriuresis and blood pressure by modulating the expression of EP1  
and EP2.
143
 Under physiological conditions, the level of PGE2 is regulated by 
three enzyme, the prostaglandin E2 synthases (PGEs), that including the 




cPGES and mPGES-2 are constitutively expressed in various cells and tissues, 
and their levels were not significantly increased under inflammatory 
conditions, but high levels of mPGES-2 was observed in human colorectal 
cancer, human gliomas and activated microglia.
145
 mPGES-1 is considered as 
an induced enzyme like COX-2, because, in normal conditions it is expressed 
at low level but under pathological conditions, this enzyme is significantly 
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A variety of signal transduction pathways are involved in the regulation of 
mPGES-1, its expression
 
increase in response to various inflammatory stimuli 
and mediators, for example, cytokines (LPS, IL-1b and TNF-α).
147,148   
It is clear how mPGES-1 could represent a drug target associated with 
inflammation, fever and pain,
149 
so, the modulation of this enzyme could be a 
promising alternative in anti inflammatory therapy. mPGES-1 plays a key role, 
similar to COX-2, in the  development of cancers. Several studies suggest that 




 head and 
neck cancer, breast cancer, stomach cancer,
153,154
 and Alzheimer‟s disease 
tissues.
155
 Furthermore, several publications reported that mPGES-1 could 
cause lung metastatic tumor formation and growth, induce EGFR expression, 
and mediate EGFR-dependent tumor growth in prostate cancer.
156 
Moreover, 
mPGES-1 expression was hugely correlated with vascular invasion and worse 
prognosis in colorectal cancer.
157158
  
Pharmacological inhibition of mPGES-1 reduced squamous carcinoma growth 
by suppression of PGE2 mediated-EGFR signalling and impairing tumor-
associated angiogenesis. These findings highlight also the potential of 
mPGES-1 inhibitors as agents capable of reducing tumor growth.
159  
The discovery of mPGES-1 is attributed to Jackbsson in 1999
160
 who 
recognized it as a member of the Membrane-Associated Proteins in Eicosanoid 
and Glutathione Metabolism (MAPEG) superfamily.
161 
In this family, there 
are many other members including leukotriene C4 synthase (LTC4S), 5-
lipoxygenase-activating protein (FLAP) and microsomal glutathione 
transferases (MGST) 1-3.
162,163
  The most closely related MAPEG member is 
the microsomal glutathione transferase-1 (MGST1), which shares 39% 
sequence identity with mPGES-1.
164  
Recently a study by Sjögren et al. showed that the accuracy of mPGES-1‟s 
structure reached a higher resolution of 1.2 Å x-ray in-plane via electron 
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 Human mPGES-1 is a membrane homotrimer with four 
transmembrane α-helices (TM1-TM4) enclosing an inner core, which looked 
like a funnel-shaped opening towards the cytoplasm between TM1 and TM2 in 
each monomer (Figure 1.6A). Glutathione (GSH) is an essential co-factor for 
active binding in the U-shapes conformation at the interface between subunits 
in the proteins
166-169
 and attacked the peroxide group of PGH2 in the active site 
via its thiol group in the catalytic cycle process.
164  
GSH forms hydrogen bond with several amino acid residues such as, Arg73, 
Asn74, Glu77, His113, Tyr117, Arg126 and Ser127 from helices II and IV, 
and Arg38 from helix I. In addition, GSH forms a π-stacking interaction with 
Tyr130 due to its glutamate and its cysteine (Figure 1.6B).  
The active site of mPGES-1 consists of three gatekeepers and a residue of Arg, 
all of that are located within the transmembrane-helix IV.
166,170-172
 In order to 
work its catalytic activity the active site of the mPGES-1 must be open to be 
able ensure the PGH2 access.
168
 The N-terminal region of helices II and IV 
jointly with the C-terminal portion of helix I and the C-cytolasmatic domain 
from neighboring molecule forms a deep cavity,
173
 researchers suggest that 
this is the active site based on the form, the size and the favorable interactions 
that this pocket has with PGH2.
174,175
  
The proposed mechanism for PGH2 isomerization to PGE2 by GSH suggests 
that Ser127 activates the thiol of GSH to form a thiolate anion that acts as 
nucleophilie and directly attack on the endoperoxide oxygen atom at the C-9 
carbon of PGH2 to produce an unstable intermediate. Deprotonation in 9-
position and cleavage of S-O bond lead to a bidentate complex with Arg126. 
This results in the regeneration of the reactive thiolate anion (regeneration of 
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Figure 1.6 (A) Structure of the mPGES-1 trimer. (B) Interactions between 
mPGES-1 and GSH. (C) Suggested mechanism of PGH2 isomerization to PGE2 by mPGES-1.  
 
Inhibition of mPGES-1 offers many therapeutic opportunities in several 
pathologies, in fact, the suppression of massive PGE2 biosynthesis is a 
reasonable pharmacological strategy in many phatological conditions such as 
fever, inflammation, cardiovascular disease and cancer.
176-178 
Traditional anti-
inflammatory agents are not selective towards this enzyme, drugs that target 
mPGES-1 are considered as valuable alternatives to NSAIDs/coxib  and they 
may offer a better safety profile and, thus, lower risk of side effects that are 
usually associated with NSAIDs and coxib.
179-182
 NSAIDs not only inhibit the 
production of PGs but also annihilates the release of bradykinin, change 
lymphocyte reactions and decrease the migration of phagocytosis of 
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granulocytes and monocyte in the inflammatory process. However, unselective 
NSAID are not able to differentiate between the two COXs, and this is the 
reason of their gastric side effects, because, PGE2 is clearly known to have the 
protective effects on the gastrointestinal mucosa.
183 
In order to overcome the 
side effects of NSAIDs selective inhibitors of the inducible COX-2 (COXibs) 
were discovered.
184 
These products modulate the COX-2 as well as the 
downstream PGEs enzymes. However, after the marketing of this class of 
medicine, they have proved to be associated with the increased cardiovascular 
risk in patients after long-term therapies, probably due to imbalance of PGI2 
and TXA2 in the vasculature.
185,186 
In this field, mPGES-1 inhibitors constitute 
an attractive pharmacological approach which could overcome the classic side 
effects associated with COX-inhibitors, in fact, blocking the mPGES-1 
enzyme we expect to selectively inhibit increased PGE2 production, without 
affecting other prostanoids of physiological importance. Despite that mPGES-
1 was reported as a drug target already in 1999, progress in  drug discovery of 
mPGES-1 has been very slow. Up to now, a number of compounds with 
different chemotypes have been identified, but none have entered clinical 
trials.
187,188 
Even today there are many problems to be studied and solved in 
developing real selective mPGES-1 modulators for humans, because, the 
phenotypic differences between human and murine enzyme have hampered 
research on the effects of mPGES-1 inhibition in cancer and in inflammatory 
diseases.
189
 For example, the variation of certain amino acids in the active site 
of mPGES-1 may lead to partial or complete loss the activity of potent 
inhibitors. Three amino acids located in transmembrane helix IV of mPGES-1 
are not conserved between human and rat/mouse enzyme, these residues are 
the gatekeepers of the active site and the variation of these amino acids 
intercept the access of modulators for steric reasons.
190 
In the Table 2 were 
reported the most known mPGES-1 inhibitors and their IC50 valeus, grouped 
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in three main ways: natural products and derivatives, synthetic compounds and 
dual inhibitors of mPGES-1 and 5-lipoxygenase (5-LO). 
Table 2. Some mPGES-1 inhibitors 














- 30 - 
 




 In cell-free assay. 
b
 Docking scores. 
c
 PGE2 production inhibition ratio. 
d
 In cell-based assay. 
 
Despite good results have been obtained for some products with different 
chemical motifs, currently there is still no selective modulators acting on 
mPGES-1 in clinics.
 217,218
 Many industrial and academic groups have worked 
to develop mPGES-1 modulators. Their results show any excellent IC50 values 
in cell-free assay but they are not stable so they have a poor cell potency, 
another reason which blocks the drug development of mPGES-1 inhibitors, as 
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previously mentioned, are the specific differences between the enzyme 
isoforms in various species.
219
 The rational inhibitors design of mPGES-1 was 
started in 2013 with the three-dimensional crystal structure of mGES-1 
determined by Sjögren et al.
165 
The rational design through computational 
methods was complicated, because, the active site is shallow and located 
within the membrane-spanning region. In 2015, a crystal structures binding to 
four inhibitors of mPGES-1 including MF63 and MK886 (see Table 2: 
synthetic inhibitors) was reported by J.G. Luz et al., they clarified the binding 
mode between inhibitors and amino acid residues and explained the 
mechanism of isomerization from PGH2 to PGE2.
220
 However, the ultimate 
goal is to discover more effective, highly selective and highly safe drugs for 
the treatment of pain, inflammatory diseases and cancer, and in this context, 
the discovery of new mPGES-1 modulators is highly demanded, so,  this 
crystal structure can expand our knowledge with regard to designing and 
pharmacologically validating inhibitors of mPGES-1.  
 
1.7 How to proceed in the research project 
 
My PhD program is aimed to the design, synthesis and biological evaluation of 
new chemical compounds able to modulate the activity of the two biological 
target described before. Therefore, the scientific activity carried out during the 
PhD was focused on the synthesis of small libraries of compounds in order to 
identify new products to guide the development of new modulators with 
inhibitory activity against the C-terminal domain of Hsp90 and mPGES-1.  
The research was focused on the analysis of data currently available in the 
literature, also taking advantage the information about Structure Activity 
Relationship (SAR) of known inhibitors of the two targets proteins. 
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 The general methodology used in this study can be described through these 
main steps: 
 
1. Analysis of data currently available in the literature in order to identify 
some chemical motifs able to interact with the two biological targets; 
2. Design and synthesis of the compounds through suitable synthetic 
strategies; 
3. Biological evaluation and individuation of new possible hits or lead 
compounds; 
4. Rationalisation of ligand/protein interaction by computational analysis. 
 
Concerning step 1, analysis data present in the literature was used for the 
identification of a few scaffolds poorly explored, able to interfere with the 
target of interest. In particular, the 3,4-dihydropyrimidin-2(1H)- one (DHPM) 
core for the Hsp90,
126
 while carbazole, dyaril and pyrazol-5-one scaffolds for 
mPGES-1.  
These chemical moieties are seen as “privileged structures” in medicinal 
chemistry, because they possess significant biological activity, in fact, 
adequately decorated, they can selectively bind many enzymes, receptors or 
channels having different pharmacological effects.
221-224  
In respect to step 2, appropriate synthetic procedures were used and optimized 
in order to obtain the desired products in good yield. For the synthesis of 
DHPM core were used the well-known Biginelli condensation, a multiple-
component chemical reaction that creates 3,4-dihydropyrimidin-2(1H)-ones 
core under acidic conditions from three component, aryl aldehydes, urea or its 
derivatives and β-ketoesters. This one-pot reaction was first reported by Pietro 
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Although the original reaction conditions suffered from poor yields, in the last 
decades, the discovery of dihydropyrimidine biological activity has led to a 
renewed exploration of the reaction conditions, revealing a variety of 
compatible solvents, acid catalysts, and an expanded substrate scope.
226
 Some 
of this procedures have replaced the traditional Brønsted acids
226-228
 with 





















Another optimization of the methodology concerned the usage of several high-
seed microwave-assisted protocols in order to improve the yield of products 
and reduce the reaction time.
239-241 
For the synthesis of our compounds, 
DHPMs derivatives have been obtained through a protocol of Biginelli 
reaction supported by microwave-irradiation and chlorotrimethylsilane 
(TMSCl).
242 
Regarding the carbazoles derivatives has been used a synthetic strategy in two 
steps, the first step was performed through a classic Suzuki-Miyaura cross-
coupling reaction in order to obtain 2-nitrobiaryl derivatives, while the second 
step was carried out via Cadogan cyclization protocol. This approach allows 
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The reaction of these compounds were conducted using an excess of triethyl 
phosphite (P(OEt)3), under solvent-free conditions and supported by 
microwave-irradiation.  
This synthetic methodology, compared to others, provides a greater tolerance 
of functional groups on the substrate and more precise regiocontrol of 
functional group placement within the product. Since the biaryl compounds 
have been obtained in the same manner of the first step of carbazole 
compounds. Suzuki-Miyaura reaction is an organic reaction between organic 
boron compounds and organic halides catalyzed by a palladium(0) complex 
and it is widely used to synthesize substituted biphenyls.
245
  
Cross-coupling reactions is one of the most straightforward methodologies for 
various carbon–carbon bond formations and it has many advantages, in fact, 
the reactants are readily available, nontoxic, and air- and water-stable.  They 
react under mild conditions and are amenable to a variety of reaction 
conditions, including the use of aqueous solvents and substrate supports. The 
inorganic boron byproduct can be easily removed after the reaction.
246
 In our 
case, biaryl compounds were obtained using a classical Suzuki-Miyaura 
protocol promoted by Pd(PPh3)4, Tetrakis(triphenylphosphine)palladium(0) 
and potassium carbonate, K2CO3 as base.  
Concerning the pyrazol-5-one derivatives has been used a synthetic strategy in 
two steps, in the first step there is the preparation of the pyrazol-5-one core 
using a tandem condensation and thermal cyclization between β-ketoesters and 
hydrazines. In the second step was performed through an aldol condensation, 
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Scheme 1.2 Synthesis of pyrazol-5-one derivatives 
 
 
Lastly concerning step 3, biological evaluation of the synthesized products 
were performed using appropriately assay for each of two investigated targets, 
e.g. Surface Plasmon Resonance (SPR), cytotoxicity, western blot assay and 
limited proteolysis assay in the case of Hsp90, a cell-free assay using the 
microsomal fraction of interleukin-1β-stimulated human A549 cells to 
evaluate the effect od several compound on mPGES-1 activity. Regarding step 
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2.1 The need to develop Hsp90 C-terminal inhibitors 
 
As outlined above, many Hsp90 N-terminal inhibitors have been 




In contrast to this strategy, an alternative approach to Hsp90 modulation for 
the treatment of cancer is represented by the C-terminal inhibitors, as they 
don't induce the heat shock response, a well-established compensatory 
mechanism that has likely limited the clinical impact of N-terminal Hsp90 
inhibitors in cancers treatments.
253-255
  
The heat shock response (HSR) is a cellular mechanism in response to stress, 
bacterial infections, heat, toxine and heavy metals.
256
  
It is mediated by heat shock factor-1 (HSF-1), which activates transcription of 
heat shock genes.
257
 HSF-1 is ubiquitously expressed and has the principal 
role in the stress-induced expression of Hsp genes,
258
 this protein is a 




In stress condition, HSF-1 is released from the chaperone complex then 
trimerized and it is transported into the nucleus where it undergoes 
hyperphosphorylation and binds to DNA containing heat shock elements 
sequence.
260, 261
 Herein it directs the trascription of Hsp genes which lead the 
increase of cellular resistance by elevating the expression of multiple heat 
shock proteins,
254
 including Hsp27, Hsp70 and Hsp90 (Figure 2.1).
262
 The N-
terminal inhibitors of Hsp90 induce the dissociation of HSF-1 from Hsp90 
and, with the same mechanism, trigger the pro-surival heat shock response that 
enables cancer cells to escape the cytotoxic effect, in fact, this cascade of 
events facilitates oncogenic growth and stops tumor cells from undergoing 
apoptosis.
263 
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                                            Figure 2.1 Heat Shock Response 
 
In addition, this attractive cytoprotective mechanism has driven researchers to 
find alternative molecules that repress Hsp90 activity without inducing HSR. 
The C-terminal modulation has an opposite effect, because C-terminal 




In this context, the research is enormously engaged in the development and 
discovery of new molecules that bind the C-terminal domain of Hsp90, but the 
vast conformational space of this region is still a strong limitation for the 
rational design of a selective inhibitors. 
 
2.2 Where do we start? 
 
With the aim of identify new promising and more potent C-terminal inhibitors 
of Hsp90 published data were used. For the first time in 2015 Strocchia et 
al.
129
 reported a new 3,4-dihydropyrimidin-2(1H)-one derivative able to 
interact with C-terminal domain of Hsp90.  
This compound was designed starting from one assumption, Csermely et al.
78, 
80
 reported that the C-terminal region is able to interact with both purine and 
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pyrimidine nucleotides (GTP and UTP preferentially), so take in advantage the 
structural analogy between uridine triphosphate (UTP) and the DHPM core 
they synthesized seventeen DHPM derivatives through Biginelli 
multicomponent reaction.   
 
Figure 2.2 First non-natural inspired modulator of C-terminal domain 
 
Moreover, compound 1 (Figure 2.2) represents the first non-natural inspired 
product able to modulate the C-terminal domain of Hsp90 with a good 
antiproliferative profile (IC50 values 50.8 ± 0.2 and 20.8 ± 0.3 mM in A375 
and Jurkat cell lines, respectively) whitout any apparent cytotoxic activity in 
non-tumor cells. Western blot analysis confirmed that the antitumor activity of 
this compound was provided by degradation of some Hsp90 client 
oncoproteins, moreover, they showed that the compound does not cause an 
increase of the levels of Hsp90 and Hsp70 demonstrating that the undesired 
HSR was not induced.  
Finally, limited proteolisis essay showed that the compound 1 binds the C-
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2.3 Influence of the chemical functionalization on the phenyl ring at C4 
position of DHPM core based Hsp90 C-terminal inhibitors. 
 
The great interest aroused by C-terminal Hsp90 inhibitors as potential 
therapeutic agent and the recent discovery of compound 1 as C-terminal 
Hsp90 inhibitor drove us to improve the exploration of this promising 
scaffold.  
With the purpose to improve the information about the structure-activity 
relationship and to explore the influence of the chemical functionalization on 
the phenyl ring at C4 position of DHPM core a second collection of different 
decorated DHPM derivatives was synthesized (compounds 2-13, Figure 2.3), 
by a microwave-assisted Biginelli multicomponent reaction
242
 through the 
combination of the following synthons: 
 
 twelve different aldehydes (A-N); 
 N-phenylurea; 
 Ethyl acetoacetate. 
N-phenylurea and ethyl acetoacetate have been used to maintain the same 
functionalizations present on the other positions on DHPM core of compound 
1. These compounds were obtained by using chlorotrimethylsilylane (TMSCl) 
as the mediator of Biginelli reaction, especially for the synthesis of N1-
substituted dihydropyrimidinones more difficult to obtain using a microwave-
assisted Biginelli protocol (Scheme 2.1).
222, 240
  
In particular, with the aim of shedding more light on the influence of chemical 
diversity around the phenyl ring at C4 position of this scaffold, diverse aryl 
aldehydes available in laboratory were chosen. These aldehydes have different 
substituents in the o-, m-, p- and o-, m- positions with either electron-
withdrawing or electron-donating groups. 
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Scheme 2.1 General synthetic procedure for the synthesis of compounds 2-13 and structures 




Following the synthetic procedure described before compounds 2-13 were 
prepared in short reaction time (15-20 min) and with a good yields (55-80%). 
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Figure 2.3 Structures of compounds 2-13 
Biological evaluation has been conducted in collaboration with Professor 
Fabrizio Dal Piaz, Dr. Maria Carmela Vaccaro and Dr. Alessandra Russo of 
Salerno University.  
 
2.3.1 Surface Plasmon Resonance assay 
Once synthesized the compounds 2-13 were evaluated for their ability to 
interact with the recombinant Hsp90α by a Surface Plasmon Resonance (SPR) 
based binding assay.
266, 267
 On the basis of this screening, 7 out of 12 tested 
compounds efficiently interact with the immobilized protein with low kinetic 
dissociation constant (KD) values (Table 2.1). The lead compound 1 and the 
known Hsp90 inhibitor 17-N-allylamino-17-demethoxygeldanamycin (17-
AAG)
268 
 were used as positive controls.Checking the results obtained 
compounds 2-6, 8 and 11 exhibit high affinity against the molecular chaperone 
with low KD values in the nM range, ranging from 2.9 to 76.2 nM. Analyzing 
the data obtained, all the compounds synthesized using p-substituted aromatic 
aldehydes were able to interact with the molecular chaperone, showing an 
increased affinity compared 1 against Hsp90 except for 2. 
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Table 2.1 Thermodynamic constants measured by SPR for the interaction between tested 
compounds and immobilized Hsp90α 
Entry KD (nM) Entry KD (nM) 
1
a 75.6  ± 7 8 2.9 ± 0.8 
2 76.2 ± 1.9 9 No Binding 
3 17.6 ± 4.9 10 No Binding 
4 13.0 ± 4.9 11 23.6 ± 0.7 
5 12.0 ± 1.9 12 No Binding 
6 3.7 ± 0.9 13 No Binding 
7 No Binding 17-AAG
a,b 388 ± 89 
a
 Data previously reported 
b
 17-N-Allylamino-17-demethoxygeldanamicin 
In addition, the presence of a nitro group at ortho position (compound 8) 
increased the affinity toward the chaperone than in para position (compound 
2) (KD 2.9 ± 0.8 nM and 76.2 ± 1.9 nM, respectively), while in the same 
position the trifluoromethyl group is not tolerated (compound 7). Moreover, 
molecules synthesized with m-substituted aldehydes (compounds 9 and 10) 
were inactive. Finally, the three products obtained by the ortho-meta 
disubstituted aromatic aldehydes showed a not homogenous results, indeed, 
compound 11 interacts with the immobilized Hsp90α with a good affinity (KD 
23.6 ± 0.7 nM), whereas 12 and 13 were inactive. 
In conclusion, this initial screening has highlighted the capacity of this second 
generation of DHPM derivatives to bind the immobilized protein.  
 
2.3.2 Antiproliferative assay and Western Blot analysis 
The new eight identified Hsp90α binders (2-6, 8, 11) were investigated for 
their potential cytotoxic effect in A375 (human melanoma) and Jurkat (human 
leukemic) cell lines. The IC50 values are reported in Table 2.2. The known C-
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terminal inhibitor novobiocin and the lead compound 1 were used as reference 
compounds in this assay.  
Antiproliferative assay has proven the cytotoxic ability of this second 
generation of DHPM derivatives, identifing three new compounds 4, 5 and 11, 
endowed with moderate cytotoxic effects at micromolar concentration in both 
cancer cell lines. 
Table 2.2 IC50 values of new binders, compound 1 and novobiocin on A375 and Jurkat cell 
lines 
 A375 Jurkat 
Entry IC50 (µM) 24h IC50 (µM) 48h IC50 (µM) 24h IC50 (µM) 48h 
2 - - - - 
3 - - - 86.1 ± 0.9 
4 - - 51.2 ± 0.8 40.3 ± 0.6 
5 85.1 ± 0.8 74.2 ± 1.1 55.0 ± 0.6 43.5 ±1.0 
6 - - - - 
8 - - - - 
11 81.0 ± 1.2 70.5 ± 1.4 21.3 ± 0.9 15.2 ± 1.1 
Novobiocin 550.3 ± 1.3 460.5 ± 0.9 170.6 ± 1.1 150.5 ± 0.7 
1
a
 50.8 ± 0.2  20.8 ± 0.3  
a
 Data previously reported 
Interestingly how all compounds show a better antiproliferative profile than 
novobiocin and a comparable profile to that remarked for the lead compound 
1. Referring to human leukemic cell line the best result was obtained for 11, 
whereas compounds 4 and 5 showed a comparable potency with an IC50 value 
around 50 µM, compound 3 shows a moderate effect only after 48h of 
treatment. Finally, the DHPM derivatives 2, 6 and 8 seem to have no effect on 
cell viability. Furthermore, these products haven not negative effect on PHA-
stimulatedproliferating PBMC, used as control non-tumor cell line, for which 
the percentage of non-viable cells after 24h of treatment was similar to that 
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observed control cells treated with DMSO. To establish that the cytotoxic 
effect pointed out by compounds 4, 5 and 11 was associated with changes of 
the Hsp90 modulation, the expression levels of some Hsp90 client 
oncoproteins was verified in the same treated and untreated cell lines used in 
the antiproliferative assay, by western blot analysis (Figure 2.4). 
Both cell lines were exposed for 24h to DMSO or 4, 5 and 11 used at 
concentrations corresponding to the IC50 values. Actin is not an Hsp90-
dependent protein and that is why it has been used as control in the 
experimental.   
 
Figure 2.4 Effect of compounds 4, 5 and 11 on Hsp90 client proteins levels in A375 and 
Jurkat cells. The shown blots are representative of three different experimental with similar 
results. 
Western blot analysis has shown that all tested compounds induced a strong 
down-regulation of Hsp90-dependent clients Raf-1 and p-Akt (about 60-80% 
less compared to untreated cells, by densitometric estimation). Notably, the 
exposure of compounds 5 and 11 in A375 and 4, 5 and 11 in Jurkat cell lines 
did not cause any significant increase in the level of Hsp90, Hsp70 and Hsp27, 
evidencing that they did not trigger the undesired HSR, unlike the 17-AAG 
which cause a marked up-regulation of Hsp90, Hsp70 and Hsp27 protein 
levels.   
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Furthermore, treatment with compounds 5 and 11 in A375 cell line for 24h has 
revealed a decrease in the Hsp27 protein levels, whereas, according with 
Sedlackova, et al.
269
 the Jurkat cell line was completely Hsp27 negative. These 
results confirm that the synthesized compounds 4, 5 and 11, as the reference 
lead compound, inhibit Hsp90 by modulation of the C-terminus 
2.3.3 Molecular docking studies 
Taken together the interesting biological results obtained by the 
dihydropyrimidin-2(1H)-scaffold and considering the poor number of 
synthetic products that modulate the Hsp90 activity at C-terminal domain, in 
collaboration with the research group of Professor Bifulco a computational 
study was performed in the attempt to explore the influence of these different 
substituents of the aromatic ring at position 4 on biological activity, leaving 
unchanged the other part of the molecule with respect to lead compound 1 
(Figure 2.5).  
Figure 2.5 3D representation of binding mode of  compound 1 and new DHPM-based 
compounds 2-13. 
This small set of molecules is closely linked to 1, so referring to the same site 
and binding mode of lead compound 1 toward Hsp90,
129
 an Induced Fit 
Docking protocol of Schrodinger Suite
270
 was used, considering the region at 
interface between the C-terminal chains of Hsp90α homologue as the area of 
pharmacologic interest. The chosen model receptor for computational analyses 
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was the ATP-bound active state of Hsp82, yeast homolog of Hsp90α (PDB 
code: 2CG9),
271
 and its sequence alignment with the human protein reported 
by Lee et al.
272 
The key interactions with Arg591 and Lys594 were considered 
as fundamental to account the inhibitory activity for this kind of molecules. In 
more details, computational analysis highlight two different binding modes for 
products with mono or disubstituted aromatic ring at C4 position: (a) the first 
subset includes compounds having the two substitutions (o, m- position), 11- 
13; (b) the second one regards compounds containing the para substitution 2-
6. Analyzing the computational results of compound 11, the presence of 
disubstituted ring at C4 position directs efficiently the binding mode in the C 










Figure 2.6 Three dimensional model of 
11(cyan sticks) and 5 (light brown sticks) 
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The bromide atom forms a crucial halogen bonds with the side chain of 
Arg591Chain B and the hydroxyl group establishes a hydrogen bonds with 
backbone of Ala597Chain A. Moreover, the dihydropyrimidin-2(1H)-one ring 
creates a π-π interaction with Arg591Chain B and two hydrogen bonds with 
Ser657Chain A and Lys594Chain A. The key role of bromide atom on the aromatic 
ring at C4 is also confirmed by the biological profile exhibited for 5, in which, 
it forms a halogen bonds with Arg591Chain B (Figure 2.6B).  
On the other hand, even if the bromide atom of compound 13 form a halogen 
bond with Ala597Chain A, the CF3 group decrease the affinity of molecule-target 
complex creating an ugly interaction with the key amino acid Arg591Chain B.  
The same trend is also observed for 12, where the CF3 group negatively affects 
its activity forming a bad interaction with the Lys423Chain B. The high 
influence of the substitution of the aromatic ring at C4 position is also 
confirmed by the complete biological inactivity of 7, in which the CF3 group 
at orto position forms a bad interaction with key Arg591Chain B drafting this 
group as not favorable in the design new Hsp90 C-terminal inhibitors. 
Considering the molecules 2-4 and 6 with para substitution (Figure 2.7), they 
show a good calculated interactions between the key aminoacids Arg591, 
Lys594 and the ring at C4.  
These results showed the fundamental role of the decoration on the phenyl 
ring at C4 position, that strongly affect the modulation of Hsp90 activity, as 
showed from a not homogeneous (4, 5 vs 2, 3 and 6) profile in 
antiproliferative assay. In conclusion, structural studies have disclosed the 
halogen bonding between bromide atom and the side chain of Arg591Chain B as 
a new key interaction suitable for the design of novel DHPM derivatives. 
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Figure 2.7 2D panels represent the interactions between 2 (A), 3 (B), 4 (C), 6 (D) and 
the residues of C-terminal Hsp90 binding site. Positive charged residues are colored in 
violet, negative charged residues are colored in red, polar residues are colored in light 
blue, hydrophobic residues are colored in green. The π-π stacking interactions are 
indicated as green lines, and H-bond (side chain) are reported as dotted pink arrows. 
 
Moreover, these findings outline that only punctual changes at specific 
position on the aromatic ring at C4 position of Biginelli‟s scaffold are 
tolerated, reflecting a high sensitive steric environment within the C-
terminal domain, and prompted us to further optimize the biginelli core 
in order to identify more powerful Hsp90 inhibitors. 
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2.4 Enhanced inhibitory activity of C-terminal Hsp90 domain through 
substitution of DHPM core at C2 position. 
 
The data so far collected have underlined an highly sensitive steric 
environment within this protein domain. In light of the findings obtained, with 
the aim of expanding the investigation on the DHPM scaffold in order to 
identify more effective Hsp90 C-terminal inhibitors, a third collection was 
synthesized by expanding the functionalization at C2 position of the DHPM 
core, which was previously unexplored (Figure 2.8).  
 
Figure 2.8 Evolution of DHPM derivatives as Hsp90 C-terminal inhibitors 
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The synthesis of this generation (compounds 15-22, Scheme 2.2) has been 
achieved in high yields using a two step procedure, under microwave-heated 
conditions.  
Briefly, in the first step were generated the dihydropyrimidine-2-thiones 
precursors 14a and 14b (Scheme 2.2) from the Biginelli reactions by means of 
the previously reported protocol, and subsequently, final desired compounds 
were obtained through a Liebeskind-Srogl cross-coupling.
273-275  
Liebeskind-Srogl reaction is a cross-coupling where a new carbon-carbon 
bond has been formed through the use of the palladium(0)-catalyzed, 
copper(I)-mediated reaction of a variety of different thioorganic products with 
boronic acids under neutral conditions.
276-278
  
The disulfitative carbon-carbon coupling requires stoichiometric amounts of a 
copper(I) carboxylate, such as Cu(I)-thiophene-2-carboxylate (CuTC) as metal 
cofactor.
279 
This cross-coupling reaction is useful for scaffold decoration of 




Hence, this synthetic procedure was exploited to synthesize compounds 15-22, 
using Tetrakis(triphenylphosphine)palladium(0) (Pd(PPh3)4) as palladium 
source, CuTC as copper(I) source and THF as solvent system, under 
microwave irradiation at 100 °C (Scheme 2.2). 
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Scheme 2.2 Structures of 15-22 and synthetic procedure
 
 
Biological evaluation has been accomplished in collaboration with Dr. Maria 
Carmela Vaccaro, Dr. Alessandra Russo of Salerno University and Dr. 
Antonio Vassallo of Basilicata University.  
 
 
2.4.1 Surface Plasmon Resonance assay 
Compounds 15-22 were evaluated for the binding to the recombinant Hsp90α 
by a Suface Plasmon Resonance (SPR)-based assay that give us a detailed 
view about their affinity toward the molecular chaperone. In Table 2.3 have 
been shown the results obtained of this preliminary screening. 
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Table 2.3 Thermodynamic constants measured by SPR for the interaction between tested 
compounds and immobilized Hsp90α 
 
Entry KD (nM) 
15 No Binding 
16 12.7 ± 3.2 
17 2.1 ± 0.9 
18 7.8 ± 1.1 
19 397 ± 3 
20 18.1 ± 4.4 
21 6.5 ± 2.7 
22 47.5 ± 9.1  
17-AAG
a 388 ± 89 
1
a
 75.6 ± 7  
a
 Data previously reported 
 
In the second generation one can see the importance of the phenyl ring at N1 
for the binding to the protein counterpart, and for this reason a directly 
analogue 15 has been synthesized. Interestingly to note the effect of the 
shifting of phenyl ring from N1 to the C2 position on the DHPM ring, in fact, 
SPR results indicated that analogue 15 did not binds to Hsp90α. Afterwards, in 
order to evaluate if a spacing out between the scaffold and the aromatic ring 
could enhance the activity, compounds 16–22 have been designed and 
synthesized. Finally, SPR data showed that all tested compounds 16–22 bind 
to Hsp90 with low KD values (Table 2.3), indicative of an optimal interaction 
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2.4.2 Antiproliferative assay, Western Blot analysis and effect on cell 
cycle progression 
The seven new identified Hsp90α binders (16-22) were tested fot their 
antiproliferative effect in A375 (human melanoma) and Panc-1 (human 
pancreatic carcinoma cell line), cells type of aggressive human cancers that 
usually acquire drug resistance in monotherapy. The amazing results obtained 
are shown in Table 2.4. 
Table 2.4 IC50 values of 16-22 in A375 and Panc-1 cell lines after 24h of treatment 
Compound IC50 (µM) in A375 IC50 (µM) in Panc-1 
16 2.5 ± 0.2 5.3 ± 0.1 
17 2.2 ± 0.1 5.0 ± 0.2 
18 2.1 ± 0.3 5.1 ± 0.2 
19 3.5 ± 0.3 6.0 ± 0.3 
20 8.7 ± 0.2 14.5 ± 0.2 
21 7.1 ± 0.1 10.0 ± 0.1 
22 4.2 ± 0.2 11.5 ± 0.2 
17-AAG 2.1 ± 0.3 >10 
 
All tested compounds exhibited a strong increased antiproliferative potency 
compared with lead 1 (IC50 50.8 ± 0.2 µM in A375). In particular, compounds 
16–18 showed the highest potency with an IC50 values about 25 fold greater 
compared to lead compound 1 against both cancer cell lines. 17-AAG (17-
(allylamino)-17- demethoxygeldanamycin), a well-known Hsp90 inhibitor, 
was used as a control in both cancer cell lines under the same experimental 
conditions. Moreover, no negative effect was observed for the above 
mentioned compounds in PHA-stimulated proliferating PBMCs, used as the 
control non-tumor cell line. In fact, the non-viable cells after 24 h of treatment 
with compounds 16–18, used with concentrations close to IC50 values (about 9 
± 1.2%, 8 ± 1.5%, 9.5 ± 1.8%, respectively), showed similar responses to that 
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observed in DMSO treated control cells (about 7 ± 0.9%). As it was done with 
the second generation, to ascertain that the cytotoxic effect of these 
compounds were associated with changes in Hsp90 modulation, the level of 
expression of some Hsp90 client protein was verified in treated and untreated 
cancer cell lines, by western blot analysis using compound 18 as a 




Figure 2.9 Western blot analysis of total cellular proteins, extracted 24 h after treatment with 
18 (2 or 5 mM), using specific antibodies. Actin was used as a loading control. The blots 
shown are representative of three different experiments with similar results 
 
Following 24h exposure to compound 18 (or 17-AAG used as a positive 
control) causes a significant down-regulation of the expression levels of client 
protein Raf-1 and p-Akt in A375 and Panc-1 cell lines. Moreover, it is worth 
to note that exposure to compound 18 did not cause any alteration in the level 
of Hsp90, Hsp70 an Hsp27 in both cancer cell lines, this means that also this 
set of molecules did not induce the undesired HSR, unlike the N-terminal 
Exploration of the structural element of 3,4-dihydropyrimidin-2(1H)-ones (DHPM) 
core, driving toward more potent Hsp90 C-terminal inhibitors 
 
- 57 - 
 
ligand 17-AAG. However, it is interesting to note the levels of Hsp27 was 
downregulated, Hsp27 prevents apoptosis and induces drug-resistance, so the 
depletion of this protein make these compounds as attractive candidates for 
drug development.  
To further investigate the cytotoxic effects induced by the most potent 
compounds 16-18, the cell cycle progression of treated cancer cells versus 
normal cell PHA-stimulated PBMC was analyzed, using flow cytometric 
analysis.
281
 The A375, Panc-1 and PBMC cells were incubated for 24h or 48h 
with concentrations close to IC50 values of 16-18. The effects of these products 
were compared to the effect of 17-AAG used at a concentration of 2 µM in 
A375 and 2.5 µM in Panc-1 cells, on the basis of a preliminary cell cycle 
distribution analysis with increasing concentrations of 17-AAG (0.5–2.5 µM) 
(data not shown).  
Previous data reported that Panc-1 cells are poorly responsive to 17-AAG after 
24 h and the exposure to 0.5 µM 17-AAG did not cause any change in the cell 
cycle distribution.
282 
Cell cycle distribution analysis indicated that 18 induced 
different responses from 17-AAG depending on the cell type. Indeed, after 
exposure of 18 the A375 cells  were mainly arrested in the G2/M phase of the 
cycle after 24 h and 48 h, with a moderate increase of the subG0/G1 DNA 
content after 48 h, indicative of apoptotic/necrotic cell death (Figure 2.10A). 
Conversely, the 18-treated Panc-1 cells were accumulated in the S and G2/M 
cell cycle phases, with a 13% fraction of subG0/G1 cells after 48 h (Figure 
2.10B).  
Moreover, 16 and 17 showed a similar effect on the cell cycle status but gave a 
smaller fraction of subG0/G1 cells after 48 h (Figure 2.10C, D). These 
products did not exhibit any pro-death or cytostatic activity in PHA-stimulated 
proliferationg PBMC (data not shown). 
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Figure 2.10 Effect of compound 18, 16  or 17 on cell cycle distribution in A375 and Panc-1 
cells. Quantification of cell cycle distribution of viable A375 (A, C) or Panc-1(B, D) cells 
treated with DMSO, compound 18, 16 or 17 (2 or 5μM, respectively) or 17-AAG (2 or 2.5 μM, 
respectively) for 24 h, S13 evaluated by PI staining. Results are expressed as means ± SD of 
three independent experiments, performed in duplicate (***P < 0.001, **P < 0.01, *P < 0.05 
versus control). 
 
2.4.3 Study of Hsp90α/18 interaction 
With the aim of identifying the Hsp90α region involved in the binding of 18, a 
limited proteolysis-mass spectrometry-based technique in analyzing the 
Hsp90α/18 complex was employed. The efficiency of this technique, in the 
investigation of Hsp90α/inhibitor interaction, relies on the evidence that 
exposed, weakly structured and flexible regions of a target protein can be 
recognized by a proteolytic enzyme and, therefore, the observed differences in 
the proteolytic patterns, in the presence or in the absence of a putative protein 





 The proteolytic patterns obtained both on Hsp90α and 
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on the Hsp90α/18 complex, using trypsin or chymotrypsin as proteolytic 
agents, are summarized in Figure 2.11. Comparing the differential peptides 
derived from the digestion of native Hsp90α or of the Hsp90α/18 complex, by 
mass spectrometry analysis, confirmed a direct interaction between 18 and the 
chaperone and it was compared to Hsp90α/novobiocin complex. 
 
Figure 2.11 Schematic representation of limited proteolysis experiments. The preferential 
cleavage sites detected on recombinant Hsp90a, Hsp90a/ novobiocin and Hsp90a/18 
complexes are indicated in black. The Hsp90a N-terminal domain is highlighted in light blue, 
the middle domain is highlighted in yellow and the C-terminal domain is highlighted in grey. 
 
Indeed, it was observed that the peptide bonds following Lys484, Lys498 and 
Lys656, preferential cleavage sites of the native chaperone in absence of 18, 
were protected in the complex, thus indicating that the middle and C-terminal 
domain of Hsp90α are likely involved in the ligand binding. In addition, the 
conformational changes of Hsp90 induced by compound 18 are similar to the 
cleavage sites detected on Hsp90α/novobiocin, a well known Hsp90 C-
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2.4.4 Molecular docking studies 
In order to rationalize the biological effects of this new set of DHPM 
derivatives, molecular docking studies between 16–22 and Hsp90α proteins 
was performed.  
As mentioned before, a yeast Hsp90α homologue (PDB code: 2CG9)
271
 was 
used as a model receptor and its sequence alignment with the human protein, 
reported by Lee et al.,
272
 was used as the reference during the comparative 
experimental–computational analysis. Considering the high plasticity of the 
Hsp90 during its mechanism of action, we have used the Induced Fit Docking 
protocol of the Schrödinger Suite
270
 was employed to account for both ligand 
and receptor flexibility.
288
 Starting from biological evaluation reported above, 
the region at interface between the C-terminal chains of Hsp90α homologue 
was considered as the area of pharmacologic interest.
127, 289
 As already 
mentioned, small structural modifications on the heterocyclic core have caused 
a shift of the site of interaction; in more detail, besides Lys640, other 
positively charged amino acids such as Arg628 and Arg670 also play a 
fundamental role in the binding of these new Hsp90 C-terminal inhibitors. In 
fact, the aromatic ring at C2 of 18 (Figure 2.12), 16 (Figure 2.13), 20 and 21 
(Figure 2.15) positively interacts with Arg628Chain A, while the phenyl ring of 
22 interacts with Arg670Chain A (Figure 2.15). Moreover, except for 15, the 
inactive one, the other molecular portions of 16–22 also form hydrogen bonds 
with Asp641Chain A and Thr638Chain A (Figure 2.12, 2.13, 2.14 and 2.15), 
contributing to the stability of the ligand–target complexes. In summary, the 
exact distances of the aromatic portion at C2 from the central core, in 
association with the best substituents on the phenyl ring at C4 position of 
DHPM core, identified from the results of the first generation (compound 1) 
and second generation (compound 11), allowed to discovery the most active 
Hsp90 C-terminal inhibitors among these three series. This new generation, in 
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fact, showed a remarkably increased of potency against A375 and overall 
against Panc-1 cancer cell lines, the more aggressive type of human tumors, 
highlighting the efficacy of Biginelli‟s scaffold as a privileged structure to 
obtain new leads in the drug discovery process. 
 
 
Figure 2.12 Three dimensional (panel A) and bi-dimensional (2D) (panel B) diagrams of 
interactions of 18 with the C-terminal domain of the HSP82 yeast analogue of Hsp90a (PDB: 
2CG9). Positively charged residues are colored in violet, negatively charged residues are 
colored in red, polar residues are colored in light blue, and hydrophobic residues are colored 
in green. The p–p and cation–p stacking interactions are indicated as green and red lines, and 
H-bonds (side chains) are indicated as dotted pink arrows. Illustrations of the 2D and 3D 
models were generated using Maestro software.
290 
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Figure 2.13 Three dimensional models (panel A and C) and 2D diagram interactions (panel B 
and D) of 15 (cyan) and 16 (orange) with C-terminal domain of HSP82 yeast analogue of 
Hsp90α (PDB: 2CG9). In the panels A and C, the protein is reported as colored ribbons: 
chain A is depicted in green and chain B is depicted in yellow. The aminoacids interacting 
with each ligand are reported in green (chain A) and yellow (chain B) sticks. In the panels B 
and D, positive charged residues are colored in violet, negative charged residues are colored 
in red, polar residues are colored in light blue, hydrophobic residues are colored in green. 
The π-π stacking interactions are indicated as green lines, and H-bond (side chain) are 
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Figure 2.14 Three dimensional models (panel A and C) and 2D diagram interactions (panel B 
and D) of 17 (blue) and 19 (light green) with C-terminal domain of HSP82 yeast analogue of 
Hsp90α (PDB: 2CG9). In the panels A and C, the protein is reported as colored ribbons: 
chain A is depicted ingreen and chain B is depicted in yellow. The aminoacids interacting with 
each ligand are reported in green (chain A) and yellow (chain B) sticks. In the panels B and 
D, positive charged residues are colored in violet, negative charged residues are colored in 
red, polar residues are colored in light blue, hydrophobic residues are colored in green. The 
π-π stacking interactions are indicated as green lines, and H-bond (side chain) are reported 
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Figure 2.15 Three dimensional models (panel A, C and E) and 2D diagram interactions 
(panel B, D and F) of 20 (pink), 21 (white), and 22 (beige) with C-terminal domain of HSP82 
yeast analogue of Hsp90α (PDB: 2CG9). In the panels A, C and E, the protein is reported as 
colored ribbons: chain A is depicted in green and chain B is depicted in yellow. The 
aminoacids interacting with each ligand are reported in green (chain A) and yellow (chain B) 
sticks. In the panels B, D and F, positive charged residues are colored in violet, negative 
charged residues are colored in red, polar residues are colored in light blue, hydrophobic 
residues are colored in green. The π-π stacking interactions are indicated as green lines, and 
H-bond (side chain) are reported as dotted pink arrows.
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Targeting mPGES-1: design and synthesis of promising inhibitors 
as new anti-inflammatory agents 
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3.1 Why mPGES-1? 
 
With the term anti-inflammatory defined each substance or treatment that 
reduces inflammation or swelling. Nowadays, the most widely used class in 
anti-inflammatory therapy are the Nonsteroidal anti-inflammatory drugs 
(NSAIDs), that act suppressing the biosynthesis of prostaglandins (PGs) 
through the activity inhibition of cyclooxygenases (COX-1/2).
291
 
Prostaglandins are bioactive mediators involved in key physiological functions 
but also in several other pathologic conditions, such as tumorigenesis.
292 
As 
descrived before, is noteworthy the correlation between inflammatory events 
and the development of pre-cancerous lesions at various anatomic sites. 
Proliferation, invasion and migration processes are promoted by inflammatory 
events and, indeed, the identification of new anti-inflammatory drugs could be 
synergic in the context of anticancer pharmacological strategies.
293
 However, 
the side effects caused by anti-inflammatory drugs currently available such as 
cardiovascular, gastrointestinal and renal side,
294
 make the development of 
safer alternatives especially for long-term therapies more required.
295, 296
 In 
this scenario, drugs that targeting mPGES-1 represent valuable approach for 
the development of new anti-inflammatory/anticancer agents with reduced 
side effects. Indeed, mPGES-1 is responsible for the biosynthesis of inducible 
PGE2 as a response to inflammatory stimuli
297
 and it doesn‟t affect on the 
constitutive levels of PGE2 involved in crucial physiological functions. Today 
there are two main strategies employed in the modulation of mPGES-1 
activity. The first consists in the negative modulation of its expression, while 
the second one concerns the direct and selective inhibition of the enzyme. 
Scientific community focused the attention on this promising target with the 
aim of developing products able to act either directly on the enzyme or to 
affect its expression. therefore, some structurally different molecules able to 
potently inhibit mPGES-1 activity have been developed. 
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3.2 Looking for new molecular platforms 
 
In literature there are various templates able to inhibit mPGES-1 activity, our 
attentions has been targeted on two molecular platforms: the 5-Pyrazolone and 
the carbazole motifs, afterwards by carbazoles compounds was obtained a 
third collection of molecules with a biaryl motif. The chosen chemical motifs 
was made through a careful search based on various inhibitors of the receptor 
counterpart,
136, 179, 188, 298 
 in addition, these scaffolds represent “privileged 




3.2.1 Design and synthesis of 5-Pyrazolone compounds 
 
For the construction of the virtual 5-pyrazolone compounds library was used 
CombiGlide software, a powerful software which allows to build in silico 
combinatorial libraries of compounds in automated manner and in a short 
time, starting from a scaffold (5-pyrazolone) of departure that will be replaced 
by user in specific positions.  
For the realization of the library have been downloaded from the Sigma-
Aldrich  database, 3012 aryl aldehydes, 23 arylhydrazines and 19 β-ketoesters. 
After that, with reagent preparation, a CombliGlide application that splits the 
various substituents on the basis of their functional group and also it allows to 
choose the part of the molecule that will bind the scaffold, the chosen building 
blocks were used as substituents of the 5-pyrazolone scaffold. Position 1 of the 
initial scaffold was substituted with the collection of the 23 arylhydrazines, 
position 3 with the collection of 19 β-keto esters and finally, position 4 with 
the collection of 3012 arylaldehydes, thus generating all possible 
combinations. 
After the construction of the virtual library, the compounds have been filtered using 
ADME/tox (absorption, distribution, metabolism, excretion and toxicity) filtering in 
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an attempt to work with databases of molecules with acceptable physical properties 
and chemical functionalities. In these perspectives has been used a Qikprop software, 
called Lipinski filter in order to eliminate the products "non-drug-like". The drug-like 
compounds were then subjected to the structure-based virtual screening towards 
mPGES-1, through the "Virtual screening workflow" form of the Schrödinger LLC.
270
 
Finally, the final products were chosen taking into account the docking score, 
selecting only those promising compounds with excellent predicted affinity towards 




Figure 3.1 (A) Graphical interface of the software CombiGlide (B) representative binding 
mode of 4-arylidene-1,3-disubstituted-5-pyrazolone. 
 
The pyrazol-5-one compounds was synthesized in two-step procedure: firstly, 
the 1,3-disubstituted-5-pyrazolones precursor 23a-23h were produced by 
refluxing in a mixture of water and ethanol using a tandem condensation and 
thermal cyclization between arylhydrazines (a-f) and appropriate β-ketoesters 
(i-iii) with a small amount of sodium acetate, subsequently, final desired 4-
arylidene-1,3-disubstituted-5-pyrazolone compounds 24-41 were obtained 
taking in advantage a reactive methylene group that react at C4 position with 
arylaldehydes (A-L) (Scheme3.1).  
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Scheme 3.1 General synthetic procedure for the synthesis of compound 24-41 and structures 
of the building blocks used to generate the 4-arylidene-1,3-disubstituted-5-pyrazolones. 
 
   
Several workers reported that the condensation of 1,3-disubstituted-5-
pyrazolones with aromatic aldehydes were performed in the presence of a 
catalyst (ethylenediammonium diacetate (EDDA),
301
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In collaboration with professor Oliver werz of Friedrich Schiller University 
(Germany), the interference of the synthesized 4-arylidene-1,3-disubstituted-5-
pyrazolones on mPGES-1 activity was investigated in a cell-free assay using 
the microsomal fration of interleukin-1β-stimulated human A549 cells. The 
tested compounds (Figure 3.2A) in most cases showed a moderate inhibitory 
activity against mPGES-1. In particular, mPGES-1 remaing activity, after 
treatment with 10 µM of 24-41, was no effected in all the case, except for 
products 24 and 33 which manifested to inhibit the enzyme of about 45% and 
50% (Figure 3.2B). 
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Figure 3.2 (A) Structures of compounds 24-41(B) Effect of compounds 24-41 on the mPGES-
1 activity. Experiments were performed in triplicate. 
 
Nevertheless, since the maximal inhibition value was lower than 50%, the IC50 




Targeting mPGES-1: design and synthesis of promising inhibitors as new anti-
inflammatory agents. 
- 72 - 
 
3.2.2 Design and synthesis of Carbazole compounds 
 
Starting from the well-known inhibitor of mPGES-1 with carbazole core,
159
 a 
small group of 2-trifluoromethyl-7(or 5)-substituted-carbazole compounds 
were designed. The synthesis of carbazole compounds recently have gained 







etc. In addition, there has 
been much interest on the biological activities of the carbazole analogues in 
recent years and a great number of carbazole alkaloids has been isolated and 
synthesized.
310 
Furthermore, the synthesis of aromatic fused systems like 
benzo- and indolocarbazoles, have found a rapidly increasing interest of the 
pharmaceutical industry due to their versatile and potent, but still scarcely 
explored, biological activities. Chimically the carbazole skeleton (Figure 3.3) 
is a modest nucleophile that can be readily functionalized with a wide variety 





Figure 3.3 Structure of carbazole ring system 
 
Electrophilic substitution reacts preferentially on the 3 and 6 position (more 
reactive) and to a lesser extent, the 1 and 8 positions, which often require more 
drastic reaction conditions. When we want to functionalize the 2, 4, 5, or 7 
ring positions, or when mono and/or asymmetrical substitution patterns are 
desidered, and/or when functional groups not easly introduced by electrophilic 
substitution are needed, other synthetic procedures are indispensable.
315
 
Fortunately several methods exist for the synthesis of carbazoles, however, the 
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majority of the work concerning the synthesis of carbazoles derivatives is 
based on the phosphite-mediated Cadogan reductive cyclization of the 
corresponding 2-nitrobiaryls.
316-318 
This synthetic method has a number of advantages which include increased 
substrate scope and functional group tolerance, and more precise regiocontrol 
of functional group placement within the product. However, this nitrene-
mediated reductive cyclization procedure often demands drastic conditions 
and long reaction times, making it a less-favored synthetic method. Today, 
microwave irradiation has emerged as a valuable tool in organic chemistry,
318-
320
 in fact, when the reactions are carried out under microwave irradiation, 
improvements in yields and reduction in reaction times are often observed. In 
particular, the synthesis of these molecules were performed in two-step 
tandem procedures: a Suzuki–Miyaura cross-coupling reaction between 1-
bromo-2-nitro-4-(trifluoromethyl) benzene and appropriate phenylboronic 
acids in order to produce the 2-nitrobiaryl precursors 42a-42e, subsequently, 
final desidered carbazoles 43-47 were obtained through a microwave-assisted 
Cadogan reductive cyclization. The reaction is commonly conducted using an 
excess of P(OEt)3 (triethyl phosphite), as both the reductant and reaction 
solvent, under microwave irradiation at a maximum irradiation power of 300 
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As mentioned above, iterference of the carbazole products with mPGES-1 
activity was investigated in a cell-free assay, using the microsomal fraction of 
interleukin-1β-stimulated human A549 cells. Unfortunately also for this 
collection of compounds have not shown inhibit the mPGES-1 activity after 
treatment with 10 and 1µM of 43-47, so an IC50 value could not be obtained 
(Figure 3.4). 
Targeting mPGES-1: design and synthesis of promising inhibitors as new anti-
inflammatory agents. 
- 75 - 
 
 
Figure 3.4 Effect of compounds 43-47 on the activity of mPGES-1. Experiments were 
performed in triplicate. 
 
Looking the results obtained by the two classes of molecules synthesized is 
right to draw some conclusions. In the case of 4-arylidene-1,3-disubstituted-5-
pyrazolones the data were not in accordance with modeling predictions, thus 
suggesting that the rational design made was not enough.  
While in the case of carbazole compounds the substitution with variously 
decorated benzyloxy groups in position 7 (or 5) is arguably not useful. In order 
to understand the binding mode of these products and rationalize the results 
obtained a molecular docking study was needed. Actually, this study showed 
how the products are not able to interact with receptor counterpart, in fact as 
shown in Figure 3.5, the representative carbazoles 43 and 46, fail to create 
good interactions with active site of mPGES-1, probably this happens for the 
planar carbazole ring system that does not allow good accommodation of the 
functional groups within the active site of mPGES-1. 
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Figure 3.5 Binding mode of 43 and 46 in the active site of mPGES-1. 
 
3.2.3 Design, synthesis and biological evaluation of Biaryl compounds 
Therefore, starting  from the assumption descibed before and with the purpose 
of optimize the few results obtained until now a collection of biaryl 
compounds has been designed. In order to synthesize the biaryl compounds a 
Suzuki-Miyaura cross-coupling reaction has been used. The Suzuki-Miyaura 
reaction is widely used for the construction of a C-C bond, because the 
building block used in this reaction are easy to handle and the experimental 
procedure is very simple. This reaction involving the coupling of an 
organoboron reagent and an organic halide in the presence of a catalyst 
(usually palladium or nickel) and a base.
322
 Basically Suzuki coupling takes 
place among an aryl- or vinyl-boronic acid acting as nucleophile with an aryl-, 
vinyl- or an alkyl-halide and is catalyzed by Ni(0) and Pd(0). As reported in 
Scheme 3.1, the mechanism of the catalytic cycle of Suzuki coupling reaction 
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Scheme 3.1 Catalytic cycle of Pd(0) in Suzuki cross-coupling reaction
 
 
The reaction begins with the oxidative addition of aryl halide to a Pd(0) 
species affording a stable trans-δ-palladium(0) complex (a). After that it 
proceeds with complete retention of configuration for alkenyl halides and with 
inversion for allylic and benzylic halides. Oxidative addition is the decisive 
step for the speed in the catalytic cycle; hence it is crucial that the supports are 
sufficiently reactives for the oxidative addition. Subsequently, the halogen 
atom bonded on the organo-palladium (II) is readily displaced by the base 
anion to provide the reactive R1-Pd-OH complex (b).
324
 Because of the low 
nucleophilicity of organic group on boron atom, the cross coupling reaction 
requires the presence of a suitable base that coordinates the organic group on 
boron atom and enhances its nucleophilicity.  
Indeed, the transmetallation of activated organic group to the Pd (II) complex 
with the consequent formation of trans R1-Pd-R2 (trans-c) is facilitated by the 
quaternization of the boron with negatively charged.
326
 Cross-coupling 
reaction has many advantages that include the mild reaction conditions, ready 
availability of organoboron reagents, which are inert to water and related 
solvents, as well as oxygen, and generally thermally stable, tolerant toward 
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various functional groups and low toxicity of starting materials and by-
products.
327,328
 Hence, this synthetic approach was employed to synthesize the 
biaryl compounds 48-64 (Figure 3.6), using Pd(PPh3)4, as a catalyst, K2CO3 as 





Figure 3.6 Structures of synthesized biaryl derivatives 48-64 
 
The first group of compounds 48-57 was synthesized using the same aryl 
halide  employed in the synthesis of precursors of the carbazole compounds in 
combination with various arylboronic acids; however, in order to increase the 
chemical variability of the substituents on the biaryl skeleton another two aryl 
halide have been used (compounds 59, 60-64). Finally, compound 58 (o-amine 
derivatives) was synthesized via nitro group reduction procedure starting from 
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the compound 51. The reduction of aromatic nitrocompound 51 to the 
corresponding amino derivative 58 was made by commercial SnCl2.2H2O (Tin 
(II) chloride dehydrate) and ethylacetate as solvent, the reaction was 
conducted in reflux condition under an inert atmosphere (Scheme 3.4). 
 




Therefore through a cell-free assay using the microsomal fraction of 
interleukin-1β-stimulated human A549 cells the interference of biaryl 
compounds with mPGES-1 activity was investigated in the same manner used 
for the first two classes of compounds (4-arylidene-1,3-disubstituted-5-
pyrazolones and carbazoles) described before. The results obtained shown that 
compounds 48-59 have no inhibitory activity toward mPGES-1, after 
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treatment with 10 µM of tested compounds, whereas compounds 60-64 
showed an amazing inhibitory activity against mPGES-1 (Figure 3.7).  
 
Figure 3.7 Effect of compounds 48-64 on the activity of mPGES-1.  
Experiments were performed in triplicate. 
Among the tested compounds, interesting IC50 values were detected for 
compounds 60-64 (Table 3.1). In particular, the best result was obtained by 
compound 63 that shows an IC50 value of 0.18 ± 0.03 µM. 
 
Table 3.1 mPGES-1 inhibition by tested compounds 60-64. Experiments were performed in 
triplicate 
Entry IC50 ± SD (µM) 
60 0.26 ± 0.09 µM 
61 0.54 ± 0.07 µM 
62 0.60 ± 0.05 µM 
63 0.18 ± 0.03 µM 
64 1.64 ± 0.08 µM 
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Analyzing the data obtained, all the tested compounds synthesized using 1-
bromo-5-fluoro-2,4-dinitrobenzene as aryl halide in the Suzuki-Miyaura 
reaction, exhibit high inhibitory activity against the mPGES-1 with low IC50 
values in the µM range, ranging from 0.18 to 1.64 µM. On the other hand, 
compound 48-57 and 59 were synthesized using the other two aryl halides (1-
bromo-2-nitro-4-(trifluoromethyl)benzene and 4-bromo-3-methylphenol) 
manifested no effect on the mPGES-1 activity, this allows to understand how 
the functionalization present on the first aromatic ring are essential for the 
inhibitory activity toward this enzyme. In conclusion, previous studies showed 
that carbazole compounds 43-47 did not interact with the active site of 
mPGES-1, so with the aim to optimize the results obtained a novel class of 
compounds has been synthesized. Promising biaryl compounds 60-64 has been 
identified as new potent mPGES-1 inhibitors. In addition, modifications of the 
nitro groups on the first aromatic ring of the biaryl skeleton were resulted in a 
loss of activity towards mPGES-1. Finally, compound 63 showed the best 
inhibitory activity on mPGES-1 (IC50 = 0.18 ± 0.03 µM) that could be a really 
promising anti-inflammatory drug realized with a simple synthetic strategy. 
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In conclusion, in the course of my PhD program an efficient approach toward 
the development of new agents able to modulate the C-terminal domain of 
Hsp90 and mPGES-1 enzyme have been discovered. In particular, with the 
aim to discover new chemical agents able to modulate C-terminal domain of 
Hsp90, we started from compound 1 which emerged as the first non-natural 
inspired inhibitor of Hsp90 C-terminus, two generation of different DHPMs 
derivatives have been synthesized. The second generation was designed in 
order to explore the chemical influence of the functionalization on the 
aromatic ring at C4 position of DHPM core, while the third generation was 
synthesized with the aim of improving the inhibitory profile of this class of 
compound through the functionalization of C2 position of Biginelli's scaffold. 
The exploration and optimization processes of DHPM core were able to 
discover the third generation possessing a better antiproliferative profile 
compared to the lead compound 1. These results support the importance of the 
DHPM core as a potent scaffold able to inhibit the C-terminal domain of 
Hsp90, moreover, these products could be useful to extend the still few 
structural knowledge related to this region. Concerning the development of 
new products able to interfere with mPGES-1 enzyme, three collections of 
compounds were successfully realized. Taking into account the molecular 
modelling studies and basing either on the highly efficient a first collection of 
4-arylidene-1,3-disubstituted-5-pyrazolone was synthesized. Whereas, taking 
in consideration the well-known carbazole inhibitor of mPGES-1, a small set 
of carbazole compounds was designed. Biological evaluation, performed in 
collaboration with the research group of professor Oliver Werz, showed that 
no compound is able to inhibit the enzyme of interest. Based on the negative 
results reported by the carbazole products a third series of biaryl compounds 
was synthesized.  
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Fortunately, biological studies of this class of molecules allowed us to identify 
five interesting products (compounds 60-64) able to inhibit the action of 












































Synthesis of second and third generation of DHPM derivatives as 
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4.1 General information 
 
All commercially available starting materials were purchased from Sigma-
Aldrich and were used as received. All solvents used for the synthesis were of 
HPLC grade; they were purchased from Sigma-Aldrich and Carlo Erba 
Reagenti. NMR spectra (1H, HMBC, HSQC) were recorded on a Bruker 400 
MHz instrument. All compounds were dissolved in 0.5 mL of 99.95% CDCl3 
(Carlo Erba, 99.95 Atom % D). Coupling constants (J) are reported in Herz, 
and chemical shifts are expressed in parts per million (ppm) on the delta (δ) 
scale relative to CHCl3 (7.26 ppm for 
1
H and 77.2 ppm for 
13
C) as internal 
reference. Electrospray mass spectrometry (ESI MS) was performed on a LCQ 
DECA TermoQuest (San Josè, California, USA) mass spectrometer. Reactions 
were monitored on silica gel 60 F254 plates (Merck) and the spots were 
visualized under UV light. Analytical and semi-preparative reversed-phase 
HPLC was performed on Agilent Technologies 1200 Series high performance 
liquid chromatography using a Jupiter Proteo C18 reversed-phase column (250 
x 4.60mm, 4μ, 90 Å, flow rate = 1 mL/min; 250 x 10.00mm, 10μ, 90 Å, flow 
rate = 4 mL/min respectively, Phenomenex
®
). The binary solvent system 
(A/B) was as follows: 0.1% TFA in water (A) and 0.1% TFA in CH3CN (B). 
The absorbance was detected at 280 nm. The purity of all tested compound 
(>97%) was determined by HPLC analysis. All microwave irradiation 
experiments were carried out in a dedicated CEM-Discover
®
 Focused 
Microwave Synthesis apparatus, operating with continuous irradiation power 
from 0 to 300 W utilizing the standard absorbance level of 300 W maximum 
power. Microwave reactions were performed on a CEM Discover® single 
mode platform using 10 mL pressurized vials. The DiscoverTM system also 
offers controllable ramp time, hold time (reaction time) and uniform stirring. 
The temperature was monitored using the CEM-Discover built-in-vertically-
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focused IR temperature sensor. After the irradiation period, the reaction vessel 
was cooled rapidly (60-120 s) to ambient temperature by air jet cooling. 
 
4.2 Methods and materials 
 
4.2.1 General procedure for synthesis of the second generation of DHPMs 
derivatives by microwave-assisted Biginelli reaction. 
 
A mixture of appropriate aldehyde (1.0 mmol), N-phenylurea (1.5 
mmol), ethyl acetoacetate (1.0 mmol) in acetonitrile (1.5 mL) was placed 
in a 10 mL microwave glass vial equipped with a small magnetic stirring 
bar. TMSCl (1.0 mmol) was added and the mixture was then stirred 
under microwave irradiation at 120°C for 15-20 min. After irradiation, 
the reaction mixture was cooled to ambient temperature by air jet 
cooling, cold water was added and the vial was poured into crushed ice 
and then at 4°C overnight. The resulting precipitate was filtered and 
washed with a cold mixture of ethanol/water (1:1) (3x3 mL), to give the 
desired product in good yields (55-80%). HPLC purification was 
performed by semi-preparative reversed-phase HPLC (on a Jupiter 
Proteo C18 column: 250 x 10.00mm, 10μ, 90 Å, flow rate = 4 mL/min) 
using the gradient conditions reported below for each compound. The 
final products were obtained with high purity (>95%) as detected by 
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Compound 2 was obtained by following the general 
procedure as a yellow solid (200.0 mg, 66% yield). 
RP-HPLC tR = 33.5 min, gradient condition: from 
5% B to 100% B in 50 min, flow rate of 4 mL/min, 
= 280 nm. 
1
H NMR (400 MHz, CDCl3): δ = 1.21 
(t, J = 7.1 Hz, 3H), 2.13 (s, 3H), 4.16 (q, J= 7.0 Hz, 
2H), 5.61 (s, 1H), 7.14 (brs, 2H), 7.41-7.50 (m, 3H), 
7.55-7.60 (d, J = 8.5 Hz, 2H), 8.22 (d, J = 8.4 Hz, 2H);
13
C NMR (100 
MHz, CDCl3): δ = 15.2, 19.6, 54.5, 61.0, 105.6, 122.6, 125.0, 128.3, 
128.9, 130.6, 133.5, 138.3, 143.4, 148.1, 166.5. ESMS, calcd for 




Compound 3 was obtained by following the general 
procedure as a yellow gelatinous solid (210.0 mg, 60% 
yield). RP-HPLC tR = 33.2 min, gradient condition: 
from 5% B to 100% B in 50 min, flow rate of 4 mL/min, 
= 280 nm. 
1
H NMR (400 MHz, CDCl3): δ = 1.21 (t, J = 
7.1 Hz, 3H), 2.13 (s, 3H), 3.80 (s, 3H), 4.16 (q, J  = 7.0 
Hz, 2H), 5.60 (s, 1H), 6.82-6.97 (m, 2H), 7.12-7.24 (m, 
4H), 7.28-7.36 (m, 3H), 8.20-8.25 (d, 2H);
13
C NMR (100 MHz, CDCl3): δ = 
14.6, 18.9, 55.0, 55.8, 60.1, 105.6, 113.8, 127.5. 128.4, 128.9, 132.8, 138.6, 









- 90 - 
 
Compound 4 was obtained by following the general 
procedure as a yellow solid (200.0 mg, 75% yield). RP-
HPLC tR = 33.9 min, gradient condition: from 5% B to 
100% B in 50 min, flow rate of 4 mL/min, = 280 nm. 
1
H NMR (400 MHz, CDCl3): δ = 1.24 (t, J  = 7.1 Hz, 
3H), 2.13 (s, 3H), 2.40 (s, 3H), 4.16 (q, J= 7.1 Hz, 2H), 
5.50 (s, 1H), 7.18-7.22 (d, J= 7.8 Hz, 2H), 7.24 (s, 1H), 
7.29-7.33 (m, 3H), 7.42-7.50 (m, 3H);
13
C NMR (100 MHz, CDCl3): δ = 15.1, 
19.6, 20.7, 55.5, 61.1, 104.9, 125.6, 127.9, 128.4, 128.9, 129.4, 136.5, 140.2, 





Compound 5 was obtained by following the general 
procedure as a yellow solid (190.0 mg, 65% yield). RP-
HPLC tR = 34.8 min, gradient condition: from 5% B to 
100% B in 50 min, flow rate of 4 mL/min, = 280 nm. 
1
H NMR (400 MHz, CDCl3): δ = 1.24 (t, J= 7.1 Hz, 
3H), 2.14 (s, 3H), 4.16 (q, J = 7.0 Hz, 2H), 5.50 (s, 1H), 
7.20 (s, 2H), 7.28-7.31 (d, J= 8.5 Hz,2H), 7.42-7.53 (m, 
5H);
13
C NMR (100 MHz, CDCl3): δ = 14.3, 19.5, 55.0, 61.3, 105.6, 122.8, 
123.4, 128.9, 129.1, 132.8, 133.5, 138.6, 143.4, 149.7, 167.3. ESMS, calcd for 
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Compound 6 was obtained by following the general 
procedure as a yellow solid (200.0 mg, 75% yield). RP-
HPLC tR = 29.4 min, gradient condition: from 5% B to 
100% B in 50 min, flow rate of 4 mL/min, = 280 nm. 
1
H NMR (400 MHz, CDCl3): δ = 1.27 (t, J = 7.1 Hz, 
3H), 2.40 (s, 3H), 4.16 (q, J= 7.0 Hz, 2H), 5.50 (s, 1H), 
6.76 (d, J=8.4 Hz,2H), 7.07 (d, J=8.3 Hz,2H), 7.18 (t, 
J=9.4 Hz,3H), 7.28 (dd, J=8.5 Hz, 2H);
13
C NMR (100 MHz, CDCl3): δ = 15.3, 
16.8, 59.1, 61.0, 114.5, 124.6, 126.3, 128.1, 129.6, 130.1, 140.2, 148.7, 115.4, 




Compound 7 was obtained by following the general 
procedure as a white solid (190.0 mg, 55% yield). RP-
HPLC tR = 36.6 min, gradient condition: from 5% B to 
100% B in 50 min, flow rate of 4 mL/min, = 280 nm. 
1
H NMR (400 MHz, CDCl3): δ = 1.04 (t, J = 7.1 Hz, 
3H), 2.28 (s, 3H), 4.02 (q, J = 7.0 Hz, 2H), 5.62 (s, 
1H), 7.29 (s, 1H), 7.45-7.52 (m, 5H), 7.66-7.69 (d, J= 6.6 Hz, 2H), 7.73-7.76 
(d, J= 7.7 Hz, 1H);
13
C NMR (100 MHz, CDCl3): δ = 14.8, 19.7, 51.2, 61.5, 
103.5, 115.1, 123.2, 127.2, 128.9, 129.3, 129.6, 130.1, 133.6, 161.9. ESMS, 
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Compound 8 was obtained by following the general 
procedure as a white solid (200.0 mg, 70% yield). 
RP-HPLC tR = 34.7 min, gradient condition: from 5% 
B to 100% B in 50 min, flow rate of 4 mL/min, = 
280 nm. 
1
H NMR (400 MHz, CDCl3): δ = 0.98 (t, J = 
7.1 Hz, 3H), 2.27 (s, 3H), 3.98 (q, J= 7.1 Hz, 2H), 
5.92 (s, 1H), 7.21-7.25 (s, 2H), 7.42-7.54 (m, 4H), 7.65-7.74 (m, 2H), 7.98 
(dd, J= 8.1, 1.3 Hz, 1H);
13
C NMR (100 MHz, CDCl3): δ = 14.8, 19.4, 51.3, 
61.1, 101.6, 123.9, 128.2, 128.5, 133.0, 135.8, 136.2, 147.3, 148.1, 150.9, 





Compound 9 was obtained by following the general 
procedure as a colorless gelatinous solid (170.0 mg, 
70% yield). RP-HPLC tR = 35.4 min, gradient 
condition: from 5% B to 100% B in 50 min, flow 
rate of 4 mL/min, = 280 nm. 
1
H NMR (400 MHz, 
CDCl3): δ = 1.23 (t, J= 7.1 Hz, 3H), 2.14 (s, 3H), 
4.16 (q, J = 7.0 Hz, 2H), 5.47 (s, 1H), 7.25 (s, 2H), 7.36 (t, J=7.2 Hz, 
1H), 7.44-7.53 (m, 5H), 7.61 (s, 1H);
13
C NMR (100 MHz, CDCl3): δ = 
15.3, 19.5, 55.1, 61.5, 105.4, 124.2, 125.7, 128.0, 128.9, 130.5, 132.4, 
147.2, 151.2, 154.9, 166.4. ESMS, calcd for C20H19BrN2O3 415.3; found 
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Compound 10 was obtained by following the 
general procedure as a white solid (200.0 mg, 70% 
yield). RP-HPLC tR = 34.2 min, gradient 
condition: from 5% B to 100% B in 50 min, flow 
rate of 4 mL/min, = 280 nm. 
1
H NMR (400 MHz, 
CDCl3): δ = 1.26 (t, J= 7.1 Hz, 3H), 2.20 (s, 3H), 
4.17 (q, J  = 7.0 Hz, 2H), 5.67 (s, 1H), 6.91 (s, 1H), 7.30 (s, 1H), 7.47-
7.53 (m, 3H), 7.63 (t, J= 8.1 Hz, 1H), 7.78 (d, J= 7.9 Hz, 1H), 8.24 (d, J= 
8.4 Hz,1H), 8.36 (s,1H);
13
C NMR (100 MHz, CDCl3): δ = 13.9, 18.4, 
53.7, 60.4, 104.0, 121.5, 122.8, 128.5, 129.5, 130.0, 132.2, 137.0, 145.2, 
148.2, 149.6, 153.1, 165.1. ESMS, calcd for C20H19BrN3O5 381.4; found 





Compound 11 was obtained by following the 
general procedure as a pale yellow gelatinous solid 
(170.0 mg, 74% yield). RP-HPLC tR = 38.7 min, 
gradient condition: from 5% B to 100% B in 50 
min, flow rate of 4 mL/min, = 280 nm. 
1
H NMR 
(400 MHz, CDCl3): δ = 1.10 (t, J = 7.1 Hz, 3H), 
2.21 (s, 3H), 4.16 (q, J = 7.1 Hz, 2H), 5.83 (s, 1H), 6.64 (dd, J = 8.6, 2.9 
Hz, 1H), 6.89 (br s, 1H), 7.17-7.24 (m, 2H), 7.39-745 (m, 4H);
 13
C NMR 
(125 MHz, CDCl3): δ = 
13
C NMR (100 MHz, CDCl3): δ = 13.9, 19.4, 
53.4, 60.2, 114.4, 115.0, 116.9, 128.9, 129.2, 129.5, 133.5, 134.4, 138.6, 
143.4, 149.7, 166.3. ESMS, calcd for C20H19BrN2O4 430.1; found m/z = 
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Compound 12 was obtained by following the 
general procedure as a white solid (150.0 mg, 70% 
yield). RP-HPLC tR = 38.2 min, gradient condition: 
from 5% B to 100% B in 50 min, flow rate of 4 
mL/min, = 280 nm. 
1
H NMR (400 MHz, CDCl3): 
δ = 1.13 (t, J = 7.1 Hz, 3H), 2.27 (s, 3H), 4.13 (q, J  
= 7.0 Hz, 2H), 5.98 (s, 1H), 7.15-7.24 (m, 2H), 7.43-7.50 (m, 3H), 7.57 
(s, 2H), 7.66 (s, 1H);
13
C NMR (100 MHz, CDCl3): δ = 15.0, 19.6, 53.9, 
61.3, 105.6, 121.9, 125.6, 127.1, 128.9, 129.8, 130.2, 129.2, 141.9, 
149.7, 167.3. ESMS, calcd for C21H18BrF3N2O3 483.3; found m/z = 




Compound 13 was obtained by following the 
general procedure as a colorless gelatinous solid 
(100.0 mg, 80% yield). RP-HPLC tR = 39.2 min, 
gradient condition: from 5% B to 100% B in 50 
min, flow rate of 4 mL/min, = 280 nm. 
1
H NMR 
(400 MHz, CDCl3): δ = 1.14 (t, J = 7.1 Hz, 3H), 
2.27 (s, 3H), 4.13 (q, J = 7.0 Hz, 2H), 5.97 (s, 1H), 7.18-7.24 (m, 2H), 
7.43-7.50 (m, 4H), 7.66 (s, 1H), 7.78 (d, J= 8.1 Hz, 1H);
13
C NMR (100 
MHz, CDCl3): δ = 14.9, 19.2, 54.9, 61.9, 105.6, 121.9, 125.6, 127.1, 
128.9, 129.8, 130.1, 129.2, 141.9, 149.7, 167.3. ESMS, calcd for 
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4.2.2 General procedure for synthesis of 14a and 14b by microwave-
assisted Biginelli reaction. 
 
A mixture of 3-ethoxybenzaldehyde (150 mg, 1.0 
mmol), thiourea (115 mg, 1.5 mmol), ethyl 
acetoacetate (130 mg, 1.0 mmol) in acetonitrile (1.5 
mL) was placed in a 10 mL microwave glass vial 
equipped with a small magnetic stirring bar. TMSCl 
(110 mg, 1.0 mmol) was added and the mixture was 
then stirred under microwave irradiation at 120°C for 20 min. After 
irradiation, the reaction mixture was cooled to ambient temperature by air jet 
cooling, cold water was added and the vial was poured into crushed ice and 
then left at 4°C overnight. The resulting precipitate was filtered and washed 
with a cold mixture of ethanol/water (1:1) (3x3 mL), to give the desired 
product as a yellow solid in 89% yields. RP-HPLC tR = 30.5 min, gradient 
condition: from 5% B to 100 % B in 50 min, flow rate of 4 mL/min, λ= 280 
nm. 
1
H NMR (300 MHz, CDCl3): δ = 1.18 (t, J = 7.1 Hz, 3H), 1.45 (t, J = 6.9 
Hz, 3H), 2.39 (s, 3H), 4.02-4.18 (m, 4H), 5.63 (s, 1H), 6.81-6.95 (m, 3H); 7.26 





A mixture of 2-bromo-5-hydroxybenzaldehyde (200 
mg, 1.0 mmol), thiourea (115 mg, 1.5 mmol), ethyl 
acetoacetate (130 mg, 1.0 mmol) in acetonitrile (1.5 
mL) was placed in a 10 mL microwave glass vial 
equipped with a small magnetic stirring bar. TMSCl 
(110 mg, 1.0 mmol) was added and the mixture was 
then stirred under microwave irradiation at 120°C for 20 min. After 
irradiation, the reaction mixture was cooled to ambient temperature by air jet 
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cooling, cold water was added and the vial was poured into crushed ice and 
then left at 4°C overnight. The resulting precipitate was filtered and washed 
with a cold mixture of ethanol/water (1:1) (3x3 mL), to give the desired 
product as a yellow solid in 89% yields. RP-HPLC tR = 26.5 min, gradient 
condition: from 5% B to 100 % B in 50 min, flow rate of 4 mL/min, λ= 280 
nm. 
1
H NMR (300 MHz, CDCl3): δ = 1.14 (t, J = 7.1 Hz, 3H); 2.47 (s, 3H); 
4.12 (m, 2H); 5.65 (s, 1H); 6.95 (br s, 1H); 7.25 (br s, 2H). ESI-MS, calcd for 




4.2.3 General procedure for microwave-assisted Liebeskind-Srogl cross 
coupling reaction 
A dry microwave process vial was charged with dihydropyrimidinethione 
precursor  14a or 14b (1.0 mmol), the appropriate boronic acid (1.5 mmol), 
CuTC (3.0 mmol), and Pd(PPh3)4 (10 mol%). The reaction vessel was 
degassed and backfilled with nitrogen three times, and through the septum 
degassed dry THF (2.0 mL) was added. The mixture was subsequently heated 
in a microwave reactor at 100 °C for 60 min. After cooling, the mixture was 
transferred to a round-bottom flask and dried under reduced pressure. A 
solution of aqueous ammonia (25%) was added and the mixture was extracted 
three times with CHCl3. The combined organic layers were dried with 
anhydrous Na2SO4 and concentrated under vacuum. The crude residue was 
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Compound 15 was obtained from 14a following the 
general procedure. A portion of the crude product 
was then purified as follows: RP-HPLC tR = 21.6 
min, gradient condition: from 5% B to 100 % B in 
50 min, flow rate of 4 mL/min, λ = 280 nm. 30.6 mg 
(85% yield, after HPLC purification step) as a pale 
yellow gelatinous solid. 
1
H NMR (400 MHz, CDCl3): δ = 1.17 (t, J = 7.1 Hz, 
3H); 1.35 (t, J = 7.1 Hz, 3H); 2.50 (s, 3H); 3.93-4.01 (m, 2H); 4.07-4.16 (m, 
2H); 5.66 (s, 1H); 6.80-6.90 (m, 3H); 7.19-7.30 (m, 3H); 7.47 (br s, 1H); 7.72 
(br s, 2H). 
13
C NMR (100 MHz, CDCl3): δ = 15.2, 15.9, 18.0, 54.5, 61.7, 64.6, 
105.4, 112.5, 117.4, 123.8, 127.1, 128.1, 129.8, 133.3, 141.4, 155.5, 163.2. 




Compound 16 was obtained from 14a by 
following the general procedure. A portion of 
the crude product was then purified as follows: 
RP-HPLC tR = 46.6 min, gradient condition: 
from 5% B to 100 % B in 80 min, flow rate of 
4 mL/min, λ = 280 nm. 16 mg (80% yield, 
after HPLC purification step) as a pale yellow gelatinous solid. 
1
H NMR (400 
MHz, CDCl3): δ = 1.13 (t, J = 7.1 Hz, 3H); 1.40 (t, J = 6.9 Hz, 3H); 2.34 (s, 
3H); 4.01 (m, 4H); 5.33 (s, 1H); 6.80 (d, J = 6.8 Hz, 2H); 6.97 (d, J = 16.1 Hz, 
1H); 7.21 (d, J = 7.9 Hz, 1H); 7.48 (s, 3H). 7.62 (m, 3H), 7.87 (d, J = 16.3 Hz, 
1H).
13
C NMR (100 MHz, CDCl3): δ = 14.8, 15.7, 18.3, 52.7, 59.2, 62.2, 103.7, 
112.0, 117.6, 118.6, 127.5, 131.3, 132.0, 141.0, 145.9, 153.1, 158.6, 162.8. 
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Compound 17  was obtained from 14a by 
following the general procedure. A 
portion of the crude product was then 
purified as follows: RP-HPLC tR = 38.9 
min, gradient condition: from 5% B to100 
% B in 70 min, flow rate of 4 mL/min, λ 
= 280 nm. 13 mg (85% yield, after HPLC purification step) as a pale yellow 
gelatinous solid. 
1
H NMR (400 MHz, CDCl3): δ = 1.12 (t, J = 7.1 Hz, 3H); 
1.42 (t, J = 7.1 Hz, 3H); 2.42 (s, 3H); 4.05 (m, 4H); 5.46 (s, 1H); 6.87-6.81 (m, 
3H); 6.99 (d, J = 16.3 Hz, 1H); 7.26 (s, 1H); 7.50 (m, 5H); 7.84 (d, J = 16.2 
Hz, 1H). 
13
C NMR (100 MHz, CDCl3): δ = 14.8, 15.7, 18.3, 52.7, 59.2, 62.2, 
103.7, 112.0, 117.6, 118.6, 127.5, 131.3, 132.0, 141.0, 145.9, 153.1, 158.6, 




Compound 18 was obtained from 14a by 
following the general procedure. A portion 
of the crude product was then purified as 
follows: RP-HPLC tR = 38.7 min, gradient 
condition: from 5% B to 100% B in 50 min, 
flow rate of 4 mL/min, λ = 280 nm. 14.8 
mg (75% yield, after HPLC purification step) as a pale yellow gelatinous 
solid. 
1
H NMR (300 MHz, CDCl3): δ = 1.10 (t, J = 7.1 Hz, 3H); 1.36 (t, J = 
7.1 Hz, 3H); 2.35 (s, 3H); 3.91-4.09 (m, 4H); 5.30 (s, 1H); 6.74-6.84 (m, 3H); 
6.96 (br s, 2H); 7.20 (t, J = 8.0 Hz, 1H); 7.39-7.49 (m, 3H); 7.60 (br s, 1H). 
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Compound 19 was obtained from 14a by 
following the general procedure. A portion 
of the crude product was then purified as 
follows: RP-HPLC tR = 37.4 min, gradient 
condition: from 5% B to 100 % B in 70 
min, flow rate of 4 mL/min, λ = 280 nm. 
10 mg (75% yield, after HPLC purification step) as a pale yellow gelatinous 
solid. 1H NMR (400 MHz, CDCl3): δ = 1.15 (t, J = 6.9 Hz, 3H); 1.41 (t, J = 
6.6 Hz, 3H); 2.41 (s, 3H); 4.05 (m, 4H); 5.39 (s, 1H); 6.82 (s, 1H); 7.52 (m, 
4H); 7.64 (m, 5H). 13C NMR (100 MHz, CDCl3): δ = 14.8, 15.7, 18.3, 52.7, 
59.2, 62.2, 103.7, 112.0, 117.6, 118.6, 127.5, 131.3, 132.0, 141.0, 145.9, 
153.1, 158.6, 162.8. ESI-MS, calcd for C24H25ClN2O3 424.9; found m/z = 
425.5 [M + H]
+ 
 
Compound 20 was obtained from 14a by 
following the general procedure. A portion 
of the crude product was then purified as 
follows: RP-HPLC tR = 29.8 min, gradient 
condition: from 5% B to 100 % B in 50 
min, flow rate of 4 mL/min, λ = 280 nm. 
10 mg (70% yield, after HPLC purification 
step) as a pale yellow gelatinous solid. 
1
H NMR (400 MHz, CDCl3): δ = 1.09 
(t, J = 7.1 Hz, 3H); 1.19 (t, J = 6.9 Hz, 3H); 2.32 (s, 3H); 2.38 (s, 3H); 4.02 
(m, 4H); 5.33 (s, 1H); 6.81 (brs, 2H); 7.10 (d, J = 7.4 Hz, 2H); 7.25 (m, 3H); 
7.42 (d, J = 7.7 Hz, 3H). 7.83 (d, J = 16.0 Hz, 1H). 
13
C NMR (100 MHz, 
CDCl3): δ = 14.8, 15.7, 18.6, 22.4, 54.9, 61.4, 64.1, 104.0, 111.0, 112.2, 113.2, 
120.5, 128.1, 130.8, 132.1, 141.6, 145.9, 148.3, 153.8, 158.9, 162.4. ESI-MS, 
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Compound 21 was obtained from 14a by 
following the general procedure. A portion 
of the crude product was then purified as 
follows: RP-HPLC tR = 48.8 min, gradient 
condition: from 5% B to 30% B in 5 min, 
increased to 100 % B in 60 min, flow rate 
of 4 mL/min, λ = 280 nm. 8 mg (60% yield, 
after HPLC purification step) as a pale yellow gelatinous solid. 
1
H NMR (400 
MHz, CDCl3): δ = 1.09 (t, J = 7.1 Hz, 3H); 1.19 (t, J = 6.9 Hz, 3H); 2.32 (s, 
3H); 3.50 (s, 3H); 4.02 (m, 4H); 5.33 (s, 1H); 6.81 (s, 2H); 7.10 (d, J = 7.4 Hz, 
2H); 7.25 (m, 3H); 7.42 (d, J = 7.7 Hz, 3H). 7.83 (d, J = 16.0 Hz, 1H). 
13
C 
NMR (100 MHz, CDCl3): δ = 14.8, 15.6, 18.2, 55.5, 61.2, 64.4, 104.1, 114.2, 
117.6, 118.6, 127.5, 131.3, 132.0, 141.0, 145.9, 153.1, 158.6, 162.8. ESI-MS, 




Compound 22 was obtained from 14b by 
following the general procedure. A portion 
of the crude product was then purified as 
follows: RP-HPLC tR= 26.6 min, gradient 
condition: from 5% B to 100 % B in 50 
min, flow rate of 4 mL/min, λ = 280 nm. 10 
mg (65% yield, after HPLC purification step) as a pale yellow gelatinous 
solid. 
1
H NMR (300 MHz, CDCl3): δ = 1.19 (t, J = 7.1 Hz, 3H); 2.69 (s, 3H); 
4.12 (m, 2H); 5.94 (s, 1H); 6.72 (m, 2H); 6.92 (s, 1H); 7.07 (t, J = 8.1 Hz, 1H); 
7.36 (d, J = 8.5 Hz, 1H); 7.53 (d, J = 7.2 Hz, 2H); 7.85 (d, J = 16.4 Hz, 1H). 
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5.1 General synthetic methods 
All commercially available starting materials were purchased from Sigma- 
Aldrich and were used as received. All solvents used for the synthesis were of 
HPLC grade; they were purchased from Sigma-Aldrich and Carlo Erba 
Reagenti. All NMR spectra were recorded on a BrukerAvance 300 or 500 
MHz instrument. All compounds were dissolved in 0.5 mL of 99.8% CDCl3 
(Sigma-Aldrich, 99.8 Atom % D). Coupling constants (J) are reported in Herz, 
and chemical shifts are expressed in parts per million (ppm) on the delta (δ) 
scale relative to CHCl3 (7.26 ppm for 
1
H and) as internal reference. 
Multiplicities are reported as follows: s, singlet; d, doublet; t, triplet; m, 
multiplet; dd, doublet of doublets. Reactions were monitored on silica gel 60 
F254 plates (Merck) and the spots were visualized under UV light. Analytical 
and semi-preparative reversedphase HPLC was performed on Agilent 
Technologies 1200 Series high performance liquid chromatography using a 
Synergi Fusion C18 reversed-phase column (250 x 4.60mm, 4μ, 80 Å, flow 
rate = 1 mL/min; 250 x 10.00mm, 10μ, 80 Å, flow rate = 4 mL/min 
respectively, Phenomenex®). The binary solvent system (A/B) was as follows: 
0.1% TFA in water (A) and 0.1% TFA in CH3CN (B). The absorbance was 
detected at 280 nm.The purity of all tested compound (>95%) was determined 
by HPLC analysis.  
 
5.2 General procedures for the preparation of 4-arylidene-1,3-
disubstituted-5-pyrazolone compounds 
 
5.2.1 General procedure for the preparation of 5-pyrazolones 23a-23h 
A mixture of appropriate β-ketoester (i-iii) (1 mmol.), arylhydrazine (a-f) (1.0 
mmol.) and sodium acetate (0.6 mmol.) in 50% ethanol (2 mL) was refluxed 
for 4 hours. After the reaction, on cooling to room temperature a brown 
precipitate appeared. The precipitate was filtered off and dried to give the 
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desidered products 23a-23h. The products were used in the next stage without 
further purification. 
 
5.2.2 General procedure for the preparation of 24-41 
A mixture of arylaldehyde (A-L) (1.3 eq.) and the appropriate 5-pyrazolone 
(23a-23h) (1.0 eq.) in acetic acid glacial (5 mL) was heated to reflux in oil 
bath for 24 h. After the reaction, the solvent was completely evaporated and 
residue was washed with cold water and filtered. The solid product was dried 
and the crude residue was purified by HPLC to give the desidered products. 
 
Compound 24 was obtained following the general 
procedures as an orange solid (190.0 mg, 65% yield). 
RP-HPLC tR = 26.6 min, gradient condition: from 5% 
B to 100% B in 50 min, flow rate of 4 mL/min, = 
240 nm. 
1
H NMR (300 MHz, CDCl3) δ 8.41 – 8.37 
(m, 1H), 8.19 (d, J = 6.6 Hz, 2H), 7.85 (dt, J = 7.1, 
2.2 Hz, 1H), 7.54 – 7.45 (m, 2H), 7.34 (d, J = 1.0 Hz, 
1H), 7.05 (d, J = 7.4 Hz, 1H), 6.76 (s, 1H), 2.17 (q, J = 8.0 Hz, 2H), 1.05 (t, J 





Compound 25 was obtained following the general 
procedures as an orange solid (150.0 mg, 60% yield). 
RP-HPLC tR = 24.5 min, gradient condition: from 
5% B to 100% B in 50 min, flow rate of 4 mL/min, 
= 240 nm. 
1
H NMR (300 MHz, CDCl3) δ 8.45 (d, J 
= 7.5 Hz, 1H), 8.38 (s, 1H), 8.28 – 8.20 (m, 3H), 7.63 
(s, 1H), 7.32 (d, J = 1.0 Hz, 1H), 7.23 (d, J = 7.4 Hz, 
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1H), 2.17 (q, J = 8.0 Hz, 2H), 1.04 (t, J = 8.0 Hz, 3H). ESI-MS, calcd for 




Compound  26 was obtained following the general 
procedures as an orange solid (100.0 mg, 62% yield). 
RP-HPLC tR = 27.2 min, gradient condition: from 
5% B to 100% B in 50 min, flow rate of 4 mL/min, 
= 240 nm. 
1
H NMR (300 MHz, CDCl3) δ 8.27 – 
8.19 (m, 2H), 8.10 (dt, J = 7.5, 5.7 Hz, 1H), 7.33 (d, 
J = 1.0 Hz, 1H), 7.23 – 7.14 (m, 2H), 7.03 (td, J = 
8.9, 2.0 Hz, 1H), 6.92 (ddd, J = 9.2, 7.5, 2.0 Hz, 1H), 
2.17 (q, J = 8.0 Hz, 2H), 1.06 (t, J = 8.0 Hz, 3H). ESI-MS, calcd for 






Compound 27 was obtained following the general 
procedures as an orange solid (90.0 mg, 60% yield). RP-
HPLC tR = 24.9 min, gradient condition: from 5% B to 
100% B in 50 min, flow rate of 4 mL/min, = 240 nm. 
1
H NMR (300 MHz, CDCl3)
 
δ 8.31 – 8.25 (m, 2H), 7.94 
– 7.88 (m, 2H), 7.58 – 7.47 (m, 3H), 7.43 – 7.38 (m, 
1H), 2.30 (s, 3H). ESI-MS, calcd for C18H11ClF3N3O3 
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Compound 28 was obtained following the general 
procedures as an orange solid (120.0 mg, 60% yield). 
RP-HPLC tR = 21.2 min, gradient condition: from 5% 
B to 100% B in 50 min, flow rate of 4 mL/min, = 
240 nm. 
1
H NMR (300 MHz, CDCl3) δ 8.31 – 8.25 
(m, 2H), 8.18 – 8.11 (m, 1H), 8.08 (q, J = 1.6 Hz, 1H), 
7.94 – 7.88 (m, 2H), 7.62 – 7.53 (m, 2H), 7.28 (d, J = 
1.1 Hz, 1H), 2.30 (s, 3H). ESI-MS, calcd for C18H13N3O5 351.3; found m/z = 






Compound 29 was obtained following the general 
procedures as an orange solid (130.0 mg, 70% yield). 
RP-HPLC tR = 26.2 min, gradient condition: from 5% 
B to 100% B in 50 min, flow rate of 4 mL/min, = 
240 nm. 
1
H NMR (300 MHz, CDCl3) δ 8.45 (d, J = 
7.5 Hz, 1H), 8.38 (s, 1H), 8.25 (d, J = 7.5 Hz, 1H), 
7.39 (d, J = 0.9 Hz, 1H), 6.97 (t, J = 7.4 Hz, 1H), 6.88 
(ddd, J = 7.6, 2.1, 1.0 Hz, 1H), 6.83 (dd, J = 7.3, 2.0 Hz, 1H), 5.93 (s, 1H), 
4.08 (q, J = 8.0 Hz, 2H), 2.72 (m, J = 6.8 Hz, 1H), 1.46 (t, J = 8.0 Hz, 3H), 
1.11 (d, J = 6.8 Hz, 6H). ESI-MS, calcd for C19H20N4O3 352.4; found m/z = 
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Compound 30 was obtained following the general 
procedures as an orange solid (150.0 mg, 75% yield). 
RP-HPLC tR = 24.5 min, gradient condition: from 5% 
B to 100% B in 50 min, flow rate of 4 mL/min, = 
240 nm. 
1
H NMR (300 MHz, CDCl3) δ 7.50 (dt, J = 
7.4, 5.7 Hz, 1H), 7.40 (d, J = 0.9 Hz, 1H), 7.04 (td, J = 
9.0, 2.0 Hz, 1H), 6.97 (t, J = 7.5 Hz, 1H), 6.94 – 6.86 
(m, 2H), 6.83 (dd, J = 7.4, 2.1 Hz, 1H), 5.93 (s, 1H), 
4.08 (q, J = 8.0 Hz, 2H), 2.17 (q, J = 8.0 Hz, 2H), 1.46 (t, J = 8.0 Hz, 3H), 1.05 






Compound 31 was obtained following the general 
procedures as an orange solid (130.0 mg, 74% yield). 
RP-HPLC tR = 23.4 min, gradient condition: from 
5% B to 100% B in 50 min, flow rate of 4 mL/min, 
= 240 nm. 
1
H NMR (300 MHz, CDCl3) δ 8.46 (d, J 
= 7.5 Hz, 1H), 8.37 (s, 1H), 8.27 (d, J = 7.5 Hz, 1H), 
7.41 (t, J = 7.5 Hz, 1H), 7.38 – 7.30 (m, 2H), 7.23 (s, 
1H), 7.19 – 7.13 (m, 1H), 7.13 – 7.07 (m, 2H), 7.02 – 
6.96 (m, 2H), 6.91 (q, J = 1.8 Hz, 1H), 2.30 (s, 3H). ESI-MS, calcd for 
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Compound 32 was obtained following the general 
procedures as an orange solid (130.0 mg, 74% yield). 
RP-HPLC tR = 23.4 min, gradient condition: from 5% B 
to 100% B in 50 min, flow rate of 4 mL/min, = 240 
nm. 
1
H NMR (300 MHz, CDCl3) δ 8.31 – 8.25 (m, 1H), 
7.94 – 7.88 (m, 1H), 7.57 – 7.51 (m, 1H), 7.24 (hept, J = 
2.1 Hz, 1H), 2.30 (s, 1H). ESI-MS, calcd for 






Compound 33 was obtained following the general 
procedures as an orange solid (120.0 mg, 80% yield). 
RP-HPLC tR = 20.4 min, gradient condition: from 5% B 
to 100% B in 50 min, flow rate of 4 mL/min, = 240 
nm. 
1
H NMR (300 MHz, CDCl3) δ 8.96 (t, J = 2.0 Hz, 
1H), 8.21 (d, J = 6.4 Hz, 2H), 8.10 (ddt, J = 22.3, 7.5, 
2.0 Hz, 2H), 7.61 (t, J = 7.5 Hz, 1H), 7.36 (d, J = 1.0 Hz, 
1H), 7.08 – 7.03 (m, 1H), 6.78 (s, 1H), 2.30 (s, 3H). 
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Compound 34 was obtained following the general 
procedures as an orange solid (130.0 mg, 68% yield). 
RP-HPLC tR = 21.8 min, gradient condition: from 5% B 
to 100% B in 50 min, flow rate of 4 mL/min, = 240 
nm. 
1
H NMR (300 MHz, CDCl3) δ 8.45 (d, J = 7.5 Hz, 
1H), 8.38 (s, 1H), 8.25 (d, J = 7.5 Hz, 1H), 7.40 (d, J = 
1.0 Hz, 1H), 6.96 (t, J = 7.4 Hz, 1H), 6.91 (ddd, J = 7.5, 
2.1, 1.0 Hz, 1H), 6.83 (dd, J = 7.3, 2.2 Hz, 1H), 5.93 (s, 
1H), 3.90 (s, 3H), 2.17 (q, J = 8.0 Hz, 2H), 1.04 (t, J = 8.0 Hz, 3H). ESI-MS, 





Compound 35 was obtained following the general 
procedures as an orange solid (130.0 mg, 65% yield). 
RP-HPLC tR = 20.4 min, gradient condition: from 5% B 
to 100% B in 50 min, flow rate of 4 mL/min, = 240 nm. 
1
H NMR (300 MHz, CDCl3) δ 8.31 – 8.25 (m, 2H), 7.94 
– 7.88 (m, 2H), 7.49 (d, J = 0.9 Hz, 1H), 7.44 (d, J = 7.5 
Hz, 1H), 6.81 – 6.72 (m, 2H), 4.59 (s, 1H), 2.30 (s, 
3H).ESI-MS, calcd for C17H12BrN3O4 402.2; found m/z 
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Compound 36 was obtained following the general 
procedures as an orange solid (130.0 mg, 70% yield). 
RP-HPLC tR = 21.4 min, gradient condition: from 5% B 
to 100% B in 50 min, flow rate of 4 mL/min, = 240 
nm. 
1
H NMR (300 MHz, CDCl3) δ 7.50 (dt, J = 7.5, 5.7 
Hz, 1H), 7.40 (d, J = 1.1 Hz, 1H), 7.04 (td, J = 8.9, 2.0 
Hz, 1H), 6.98 (d, J = 7.4 Hz, 1H), 6.96 – 6.86 (m, 2H), 
6.83 (dd, J = 7.4, 2.1 Hz, 1H), 5.93 (s, 1H), 3.90 (s, 3H), 
2.17 (q, J = 8.0 Hz, 2H), 1.05 (t, J = 8.0 Hz, 3H). ESI-MS, calcd for 






Compound 37 was obtained following the general 
procedures as an orange solid (110.0 mg, 60% yield). 
RP-HPLC tR = 25.4 min, gradient condition: from 
5% B to 100% B in 50 min, flow rate of 4 mL/min, 
= 240 nm. 
1
H NMR (300 MHz, CDCl3) δ 8.31 – 
8.25 (m, 2H), 7.94 – 7.88 (m, 2H), 7.41 (d, J = 0.9 
Hz, 1H), 7.02 (s, 1H), 6.72 (d, J = 1.0 Hz, 1H), 5.75 
(s, 1H), 3.90 (s, 3H), 2.30 (s, 3H). ESI-MS, calcd for C18H14BrN3O5 432.2; 
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Compound 38 was obtained following the general 
procedures as a solid (130.0 mg, 70% yield). RP-
HPLC tR = 21.4 min, gradient condition: from 5% B 
to 100% B in 50 min, flow rate of 4 mL/min, = 240 
nm. 
1
H NMR (300 MHz, CDCl3) δ 8.45 (d, J = 7.5 
Hz, 1H), 8.38 (s, 1H), 8.25 (d, J = 7.5 Hz, 1H), 7.40 
(d, J = 1.1 Hz, 1H), 6.97 (t, J = 7.4 Hz, 1H), 6.90 (ddd, 
J = 7.5, 2.1, 1.0 Hz, 1H), 6.83 (dd, J = 7.4, 2.1 Hz, 
1H), 5.93 (s, 1H), 4.08 (q, J = 8.0 Hz, 2H), 2.17 (q, J = 8.0 Hz, 2H), 1.46 (t, J 
= 8.0 Hz, 3H), 1.04 (t, J = 8.0 Hz, 3H)..ESI-MS, calcd for C18H18N4O3 338.3; 






Compound 39 was obtained following the general 
procedures as a solid (110.0 mg, 66% yield). RP-HPLC 
tR = 23.8 min, gradient condition: from 5% B to 100% B 
in 50 min, flow rate of 4 mL/min, = 240 nm. 
1
H NMR 
(300 MHz, CDCl3)  δ 8.24 – 8.16 (m, 2H), 8.03 – 7.96 
(m, 2H), 7.84 – 7.78 (m, 2H), 7.36 (d, J = 1.0 Hz, 1H), 
7.05 (d, J = 7.4 Hz, 1H), 6.78 (s, 1H), 2.30 (s, 3H). ESI-
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Compound 40 was obtained following the general 
procedures as a solid (120.0 mg, 76% yield). RP-
HPLC tR = 26.8 min, gradient condition: from 5% B 
to 100% B in 50 min, flow rate of 4 mL/min, = 240 
nm. 
1
H NMR (300 MHz, CDCl3)  δ 8.45 (dt, J = 2.2, 
1.2 Hz, 1H), 7.85 (dt, J = 7.0, 2.2 Hz, 1H), 7.54 – 7.45 
(m, 2H), 7.41 (d, J = 0.9 Hz, 1H), 6.97 (t, J = 7.5 Hz, 
1H), 6.89 (ddd, J = 7.5, 2.0, 1.0 Hz, 1H), 6.83 (dd, J = 7.4, 2.1 Hz, 1H), 5.93 
(s, 1H), 4.08 (q, J = 8.0 Hz, 2H), 2.17 (q, J = 8.0 Hz, 2H), 1.46 (t, J = 8.0 Hz, 
3H), 1.05 (t, J = 8.0 Hz, 3H). ESI-MS, calcd for C21H19F3N2O3 404.3; found 






Compound 41 was obtained following the 
general procedures as a solid (132.0 mg, 80% 
yield). RP-HPLC tR = 28.9 min, gradient 
condition: from 5% B to 100% B in 50 min, 
flow rate of 4 mL/min, = 240 nm. 
1
H NMR 
(300 MHz, CDCl3) δ 8.55 – 8.50 (m, 1H), 
8.03 (dt, J = 7.5, 2.0 Hz, 1H), 7.91 – 7.83 (m, 
2H), 7.70 (dt, J = 7.7, 1.8 Hz, 1H), 7.50 (dt, J = 14.6, 7.4 Hz, 3H), 7.29 (d, J = 
7.5 Hz, 1H), 7.10 (d, J = 7.5 Hz, 1H), 6.17 (s, 1H), 2.17 (q, J = 8.0 Hz, 2H), 
1.05 (t, J = 8.0 Hz, 3H).ESI-MS, calcd for C24H16F6N2O2 478.4; found m/z = 
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5.3 General procedure for the synthesis of carbazole compounds  
5.3.1 General procedure for the preparation of 42a-42e 
To a 25-mL flask was added a mixture of 1-bromo-2-nitro-4-(trifluoromethyl) 
benzene (0.18 mmol; 1 eq.), the appropriate phenylboronic acid (0.22 mmol; 
1.2 eq.), K2CO3 (0.37 mmol; 2 eq.) and Pd(PPh3)4 (5% mmol). The flask was 
evacuated and backfilled with nitrogen three times.Degassed 1-4 dioxane (0.8 
ml) and degassed water (0.4 ml) were added by means of an air-tight syringe. 
The reaction mixture was heated to reflux and stirred overnight under nitrogen 
atmosphere. After the solvent was removed under reduced pressure and the 
crude was taken up in diethyl ether. The precipitated was filtered through a 
Celite pad and washed with diethyl ether and concentrated in vacuo to give the 
desidered products 42a-42e, the products were used in the next step without 
further purification. 
 
5.3.2 General procedure for synthesis of 43-47. 
The nitro compounds 42a-42e were suspended in triethyl phosphate (3 mL) in 
a tightly sealed 10 mL glass vial and was irradiated at a maximum irradiation 
power of 300 W for 15 min at a pre-selected temperature of 210 °C. After the 
reaction, the vial was cooled to 50 °C by gas jet cooling and the contents were 
transferred to a 50 mL flask with the help of EtOAc (10 mL). After cooling to 
r.t., the mixture was partitioned between H2O and EtOAc (20 mL each) and 
the aqueous layer was further extracted with EtOAc (3 × 10 mL). The 
combined organic layers were dried over NaSO4 and solvents were removed 
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Compound 43 was obtained following the 
general procedures as a white solid (114.0 
mg, 70% yield). RP-HPLC tR = 35.9 min, 
gradient condition: from 5% B to 100% B in 
50 min, flow rate of 4 mL/min, = 220 nm. 
1
H NMR (500 MHz, CDCl3) δ 8.03 (t, J = 
7.4 Hz, 2H), 7.78 (d, J = 1.6 Hz, 1H), 7.71 
(d, J = 1.4 Hz, 1H), 7.61 (s, 1H), 7.47 (dd, J = 7.5, 1.5 Hz, 1H), 7.38 – 7.30 
(m, 2H), 7.23 (dq, J = 4.2, 2.0 Hz, 2H), 7.07 (dt, J = 7.5, 2.0 Hz, 1H), 5.11 (s, 
2H).  
 
Compound 44 was obtained following the general 
procedures as a white solid (110.0 mg, 65% yield). 
RP-HPLC tR = 34.9 min, gradient condition: from 5% 
B to 100% B in 50 min, flow rate of 4 mL/min, = 
220 nm. 
1
H NMR (500 MHz, CDCl3) δ 7.95 (d, J = 
7.5 Hz, 1H), 7.78 (d, J = 1.4 Hz, 1H), 7.63 – 7.56 (m, 
2H), 7.42 (dd, J = 7.5, 1.5 Hz, 1H), 7.39 – 7.31 (m, 
3H), 7.28 – 7.22 (m, 2H), 7.11 (dt, J = 7.3, 2.0 Hz, 1H), 5.12 (s, 2H).  
 
Compound 45 was obtained following 
the general procedures as a white solid 
(122.0 mg, 75% yield). RP-HPLC tR = 
32.6 min, gradient condition: from 5% 
B to 100% B in 50 min, flow rate of 4 mL/min, = 220 nm. 
1
H NMR (500 
MHz, CDCl3) δ 8.02 (dd, J = 7.5, 4.4 Hz, 2H), 7.78 (d, J = 1.6 Hz, 1H), 7.71 
(d, J = 1.4 Hz, 1H), 7.61 (s, 1H), 7.47 (dd, J = 7.5, 1.5 Hz, 1H), 7.35 – 7.26 
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Compound 46 was obtained following the 
general procedures as a white solid (105.0 
mg, 65% yield). RP-HPLC tR = 36.8 min, 
gradient condition: from 5% B to 100% B in 
50 min, flow rate of 4 mL/min, = 220 nm. 
1
H NMR (500 MHz, CDCl3) δ 8.34 (d, J = 7.5 
Hz, 1H), 8.28 (dd, J = 7.3, 1.6 Hz, 1H), 8.15 
(t, J = 7.2 Hz, 2H), 7.78 (dd, J = 9.7, 1.6 Hz, 
3H), 7.66 (s, 1H), 7.54 – 7.38 (m, 4H), 7.34 (dd, J = 7.5, 1.5 Hz, 1H), 7.01 (dd, 
J = 7.4, 1.4 Hz, 1H), 5.11 (s, 2H). 
 
Compound 47 was obtained following the 
general procedures as a white solid (95.0 
mg, 70% yield). RP-HPLC tR = 39.2 min, 
gradient condition: from 5% B to 100% B 
in 50 min, flow rate of 4 mL/min, = 220 
nm. 
1
H NMR (500 MHz, CDCl3) δ 8.02 
(t, J = 7.1 Hz, 2H), 7.78 (d, J = 1.6 Hz, 
1H), 7.71 (d, J = 1.5 Hz, 1H), 7.60 (s, 
1H), 7.47 (dd, J = 7.5, 1.5 Hz, 1H), 7.33 
(dd, J = 7.6, 1.5 Hz, 1H), 7.15 (dt, J = 7.6, 1.1 Hz, 2H), 6.95 – 6.88 (m, 2H), 
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5.3.3 General procedure for the synthesis of biaryl compounds   
To a 25-mL flask was added a mixture of aryl halide (i-iii, 0.18 mmol; 1 eq.), 
commercially available phenylboronic acid (A-L, 0.22 mmol; 1.2 eq.), K2CO3 
(0.37 mmol; 2 eq.) and Pd(PPh3)4 (5% mmol).The flask was evacuated and 
backfilled with nitrogen three times.Degassed 1-4 dioxane (0.8 ml) and 
degassed water (0.4 ml) were added by means of an air-tight syringe. The 
reaction mixture was heated to reflux and stirred overnight under nitrogen 
atmosphere. After the solvent was removed under reduced pressure and the 
crude was taken up in diethyl ether. The precipitated was filtered through a 
Celite pad and washed with diethyl ether and concentratedin vacuo. The crude 
residue was purified by HPLC to give the pure products in good yields (70-
90%) and high purity (>95%). 
 
Compound 48 was obtained by 
following the general procedure as 
a yellow solid (90% yield). RP-
HPLC tR = 31.5 min, gradient 
condition: from 5% B to 40% B in 
5 min, increased to 100% B in 40 min, λ = 240 nm. 
1
H NMR (300 MHz, 
CDCl3) δ 8.17 (d, J = 1.8 Hz, 1H), 7.92 (dd, J = 8.1, 1.8 Hz, 1H), 7.64 (d, J = 
8.0 Hz, 1H), 7.57 (d, J = 8.2 Hz, 2H), 7.45 (t, J = 8.0 Hz, 1H), 7.41 – 7.37 (m, 
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Compound 49 was obtained by following the 
general procedure as a yellow solid (90% yield). 
RP-HPLC tR = 36.6 min, gradient condition: from 
5% B to 40% B in 5 min, increased to 100% B in 
50 min, λ = 240 nm.
1
H NMR (300 MHz, CDCl3): δ =8.29 (s, 1H), 7.87 (dd, J 
= 8.1, 1.8 Hz, 1H), 7.60 (dd, J = 7.8, 4.7 Hz, 2H), 7.52 (td, J = 7.6, 1.4 Hz, 
1H), 7.47 (td, J = 7.6, 1.4 Hz, 1H), 7.35 (t, J = 8.0 Hz, 1H), 7.25 – 7.17 (m, 
2H), 7.01 (t, J = 2.0 Hz, 1H), 6.96 (dd, J = 8.4, 2.5 Hz, 1H), 4.92 – 4.81 (m, 
2H). 
 
Compound 50 was obtained by 
following the general procedure as a 
yellow solid (90% yield). RP-HPLC tR = 
27.4 min, gradient condition: from 5% B 
to 40% B in 5 min, increased to 100% B in 40 min, λ = 240 nm. 
1
H NMR (300 
MHz, CDCl3) δ 8.17 (d, J = 1.9 Hz, 1H), 8.04 (dd, J = 7.7, 1.9 Hz, 1H), 7.94 
(d, J = 7.5 Hz, 1H), 7.64 – 7.56 (m, 4H), 7.30 (t, J = 7.5 Hz, 2H), 6.99 – 6.87 
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Compound 51 was obtained by 
following the general procedure as a 
yellow solid (90% yield). RP-HPLC tR 
= 29.8 min, gradient condition: from 
5% B to 40% B in 5 min, increased to 100% B in 40 min, λ = 240 nm. 
1
H 
NMR (300 MHz, CDCl3) δ 9.34 (t, J = 7.5 Hz, 1H), 8.27 (dd, J = 7.4, 1.5 Hz, 
1H), 8.18 (t, J = 1.5 Hz, 1H), 8.08 – 8.02 (m, 1H), 7.95 (d, J = 7.5 Hz, 1H), 
7.78 (dt, J = 7.4, 1.6 Hz, 1H), 7.67 (dd, J = 7.3, 1.3 Hz, 2H), 7.64 – 7.59 (m, 
2H), 7.50 (td, J = 7.4, 1.6 Hz, 1H), 7.47 – 7.38 (m, 2H), 6.99 (dd, J = 7.5, 1.4 
Hz, 1H), 5.11 (s, 2H). 
 
Compound 52 was obtained by following the 
general procedure as a yellow solid (90% yield). 
RP-HPLC tR = 29.8 min, gradient condition: 
from 5% B to 40% B in 5 min, increased to 
100% B in 40 min, λ = 240 nm. 
1
H NMR (300 
MHz, CDCl3) δ 8.29 (d, J = 1.7 Hz, 1H), 8.14 – 8.08 (m, 1H), 7.95 (d, J = 7.5 
Hz, 1H), 7.86 (dd, J = 7.4, 2.1 Hz, 1H), 7.59 – 7.50 (m, 2H), 7.50 – 7.42 (m, 
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Compound 53 was obtained 
by following the general 
procedure as a yellow solid 
(75% yield). RP-HPLC tR = 
32.2 min, gradient condition: from 5% B to 40% B in 5 min, increased to 
100% B in 40 min, λ = 240 nm. 
1
H NMR (300 MHz, CDCl3) δ 8.18 (dd, J = 
1.9, 0.9 Hz, 1H), 8.08 – 8.02 (m, 1H), 7.94 (d, J = 7.4 Hz, 1H), 7.59 (s, 4H), 
7.16 (dt, J = 7.6, 1.2 Hz, 2H), 6.90 – 6.83 (m, 2H), 5.05 (s, 2H), 3.48 (t, J = 4.3 
Hz, 2H), 3.23 (s, 3H), 2.76 – 2.70 (m, 2H). 
 
Compound 54 was obtained by following 
the general procedure as a yellow solid 
(85% yield). RP-HPLC tR = 30.2 min, 
gradient condition: from 5% B to 40% B 
in 5 min, increased to 100% B in 40 min, λ = 240 nm. 
1
H NMR (300 MHz, 
CDCl3) δ 8.23 – 8.19 (m, 1H), 8.06 (dd, J = 7.5, 1.9 Hz, 1H), 7.95 (d, J = 7.4 
Hz, 1H), 7.66 – 7.58 (m, 2H), 7.41 (dd, J = 7.5, 2.0 Hz, 1H), 7.30 (t, J = 7.5 
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Compound 55 was obtained by 
following the general procedure 
as a yellow solid (77% yield). 
RP-HPLC tR = 30.2 min, gradient 
condition: from 5% B to 40% B 
in 5 min, increased to 100% B in 
40 min, λ = 240 nm. 
1
H NMR (300 MHz, CDCl3) δ 8.24 – 8.19 (m, 1H), 8.05 
(dd, J = 7.7, 1.9 Hz, 1H), 7.94 (d, J = 7.4 Hz, 1H), 7.66 – 7.60 (m, 2H), 7.40 
(dd, J = 7.5, 2.0 Hz, 1H), 6.14 (d, J = 2.0 Hz, 2H), 6.08 (t, J = 2.0 Hz, 1H), 
5.12 (d, J = 1.0 Hz, 2H), 3.84 (s, 6H). 
 
 
Compound 56 was obtained by 
following the general procedure as a 
yellow solid (77% yield). RP-HPLC 
tR = 31.5 min, gradient condition: 
from 5% B to 40% B in 5 min, 
increased to 100% B in 40 min, λ = 240 nm. 
1
H NMR (300 MHz, CDCl3) δ 
8.18 (d, J = 1.8 Hz, 1H), 8.03 (dd, J = 7.5, 1.9 Hz, 1H), 7.92 (d, J = 7.5 Hz, 
1H), 7.43 – 7.36 (m, 5H), 7.23 (dd, J = 6.6, 2.0 Hz, 2H), 6.82 (dt, J = 7.5, 2.0 
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Compound 57 was obtained by 
following the general procedure as a 
yellow solid (79% yield). RP-HPLC tR 
= 31.2 min, gradient condition: from 5% 
B to 40% B in 5 min, increased to 100% 
B in 40 min, λ = 240 nm. 
1
H NMR (300 MHz, CDCl3) δ 8.19 – 8.14 (m, 1H), 
8.01 (dt, J = 7.6, 1.5 Hz, 1H), 7.88 (d, J = 7.5 Hz, 1H), 7.48 – 7.43 (m, 2H), 
7.43 – 7.36 (m, 1H), 7.31 – 7.20 (m, 3H), 7.16 (dt, J = 7.5, 2.0 Hz, 1H), 6.82 
(dt, J = 7.5, 2.0 Hz, 1H), 5.12 (d, J = 0.9 Hz, 2H). 
 
Compound 59 was obtained by 
following the general procedure as 
a yellow solid (70% yield). RP-
HPLC tR = 27.2 min, gradient 
condition: from 5% B to 40% B in 
5 min, increased to 100% B in 40 min, λ = 240 nm. 
1
H NMR (300 MHz, 
CDCl3) δ 7.60 (dt, J = 7.4, 1.1 Hz, 2H), 7.57 – 7.51 (m, 2H), 7.37 – 7.28 (m, 
2H), 7.25 – 7.17 (m, 2H), 7.03 (dt, J = 7.5, 2.0 Hz, 1H), 6.83 – 6.75 (m, 2H), 
5.05 (d, J = 1.4 Hz, 2H), 2.30 (d, J = 1.1 Hz, 3H).  
  
Compound 60 was obtained by 
following the general procedure as 
a white solid (85% yield). RP-
HPLC tR = 23.8 min, gradient 
condition: from 5% B to 40% B in 
5 min, increased to 100% B in 40 
min, λ = 280 nm.
1
H NMR (300 MHz, CDCl3): δ = 8.86 (d, J = 1.6 Hz, 1H), 
7.58 (d, J = 8.1 Hz, 2H), 7.46 (t, J = 8.0 Hz, 1H), 7.40 – 7.37 (m, 2H), 7.27 (d, 
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 Compound 61 was obtained by following the general 
procedure as a white solid (90% yield). RP-HPLC tR = 
24.3 min, gradient condition: from 5% B to 40% B in 
5 min, increased to 100% B in 40 min, λ = 280 nm. 
1
H 
NMR (400 MHz, CDCl3): δ = 8.95 (s, 1H), 7.64 – 7.57 
(m, 1H), 7.57 – 7.46 (m, 2H), 7.37 (t, J = 8.0 Hz, 1H), 
7.23 (tt, J = 3.4, 1.7 Hz, 3H), 7.05 – 6.94 (m, 2H), 4.95 
– 4.81 (m, 2H).
  
 
Compound 62 was obtained by 
following the general procedure as an 
orange solid (70% yield). RP-HPLC tR 
= 24.7 min, gradient condition: from 
5% B to 40% B in 5 min, increased to 
100% B in 40 min, λ = 280 nm.
1
H NMR (400 MHz, CDCl3): δ = 8.78 (s, 1H), 
7.51 – 7.42 (m, 3H), 7.42 – 7.36 (m, 1H), 7.31 – 7.27 (m, 3H), 7.24 (s, 1H), 
7.12 – 7.06 (m, 2H), 5.15 (s, 2H).
   
 
Compound 63 was obtained by 
following the general procedure as a 
yellow solid (90% yield). RP-HPLC 
tR = 36.5 min, gradient condition: 
from 5% B to 40% B in 5 min, 
increased to 100% B in 60 min, λ = 
280 nm.
1
H NMR (400 MHz, CDCl3): δ = 8.85 (s, 1H), 8.43 – 8.34 (m, 1H), 
7.89 – 7.82 (m, 1H), 7.68 (d, J = 8.0 Hz, 2H), 7.60 – 7.47 (m, 3H), 7.47 – 7.36 
(m, 3H), 7.28 (s, 1H), 6.94 (d, J = 7.6 Hz, 1H), 5.36 (s, 2H). 
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Compound 64 was obtained 
by following the general 
procedure as a yellow solid 
(90% yield). RP-HPLC tR = 
36.5 min, gradient 
condition: from 5% B to 
40% B in 5 min, increased to 100% B in 60 min, λ = 280 nm.
1
H NMR (400 
MHz, CDCl3): δ = 8.85 (s, 1H), 7.57 (d, J = 8.1 Hz, 2H), 7.39 – 7.34 (m, 2H), 
7.26 (s, 1H), 7.20 (d, J = 8.5 Hz, 2H), 6.98 – 6.94 (m, 2H), 5.14 (s, 2H), 3.62 
(t, J = 7.1 Hz, 2H), 3.40 (s, 3H), 2.88 (t, J = 7.1 Hz, 2H). 
 
5.3.3.1 Synthesis of 58 
To 5 mL of a EtOH solution containing 51 (1.0 equiv) was added stannous 
chloride dehydrate ( 5.0 equiv) and the reaction mixture was refluxed for 18 h. 
The reaction mixture was evaporated and extracted with ethyl ether and NaOH 
solution. The resulted suspension was then filtered with Celite. The filter cake 
was washed with ethyl ether while the filtrate was extracted with ethyl ether. 
The organic layers were combined, dried over anhydrous Na2SO4 and 
concentrated under vacuum. 
Compound 58 was obtained by 
following the general procedure as a 
yellow solid (65% yield). RP-HPLC 
tR = 28.5 min, gradient condition: 
from 5% B to 40% B in 5 min, 
increased to 100% B in 60 min, λ = 
240 nm. 
1
H NMR (300 MHz, CDCl3) δ 9.34 (t, J = 7.5 Hz, 1H), 8.30 (dd, J = 
7.5, 1.5 Hz, 1H), 7.78 (dt, J = 7.5, 1.6 Hz, 1H), 7.70 – 7.59 (m, 4H), 7.50 (td, J 
= 7.4, 1.6 Hz, 1H), 7.47 – 7.38 (m, 2H), 7.22 – 7.17 (m, 2H), 7.14 (dd, J = 7.6, 
2.0 Hz, 1H), 6.90 – 6.85 (m, 1H), 5.11 (s, 2H). 
 
Experimental Section 
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